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Mechanotransduction is the process of mechanical information transfer between a cell 
and its surroundings into biochemical responses. Involved in mechanotransduction are 
several components: extracellular matrix (ECM), transmembrane integrin receptors, focal 
adhesion protein complexes, and actin stress fibers. Through these complex interactions, 
cells can exert contractile forces and migrate, proliferate, change morphology and 
differentiate in the case of stem cells. It has been suggested in the literature that 
mechanotransductive effects vary between two-dimensional (2D) and three-dimensional 
environments (3D). 
Objectives: In this study, four inhibitors were tested to determine the critical points 
(concentrations) affecting mechanotransduction. The used inhibitors were PF-562271, a 
focal adhesion kinase (FAK) inhibitor, PD98059, a mitogen-activated protein kinase 
kinase (MEK) inhibitor, Y-27632, a Rho-associated protein kinase (ROCK) inhibitor and 
(-)-Blebbistatin, a non-muscle myosin II (NMMII) inhibitor. Although all four inhibitors 
have previously been studied, critical concentrations at which these inhibitors affect 
human bone marrow stromal cell (hBMSC) survival is unclear. In addition, the effects on 
morphology and viability are poorly reported, both in 2D and 3D. 
Methods: The critical points of four inhibitors were assessed based on two aspects: 
viability and morphology. Various concentrations of the inhibitors were applied to cell 
cultures for 24 h or 48 h. After the exposure time in 2D and 3D models, cells were imaged 
for morphological changes (n=2) and tested for their viability (n=5 and n=3, respectively). 
Tissue culture plastic/glass and rat collagen I hydrogel were used as a 2D and 3D models, 
respectively. 
Results: IC50 was successfully calculated for FAK inhibitor in both 2D and 3D model 
(3.5 µM and 5.2 µM, respectively) and for Blebbistatin in 2D (28.5 µM). ROCK inhibitor 
had little effect on viability, but based on morphological changes IC50 of 6 µM was 
estimated. MEK inhibitor had no clear effect on viability or morphology of the cells.  
Conclusion: Based on the results achieved in the present study, new information was 
obtained concerning all four inhibitors. In addition, the results correlate the hypotheses 
of the present study and the mechanotransductive signaling pathway hierarchy. 
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Mekanotransduktio on mekaanisen informaation muuntamista biokemialliseksi vasteeksi 
solun ja sen ympäristön välillä. Prosessissa on osallisena useita komponentteja: 
soluväliaine (ECM), integriinit, fokaaliadheesio proteiinikompleksit ja aktiini-
stressisäikeet. Näiden yhteyksien kautta solu muodostaa solunsisäisen jännitteen ja 
kykenee liikkumaan, jakautumaan, muuttamaan morfologiaa sekä erilaistumaan 
kantasolujen tapauksessa. Kirjallisuuden mukaan mekanotransduktiiviset vaikutukset 
poikkeavat toisistaan kaksi- (2D) ja kolmiulotteisessa (3D) ympäristössä. 
Tässä työssä pyrittiin määrittelemään kriittinen piste, konsentraatio, neljälle 
inhibiittorille, jotka vaikuttavat solun mekanotransduktion signalointipolkuihin. Valitut 
inhibiittorit olivat fokaaliadheesio kinaasi (FAK) -inhibiittori PF-562271, mitogeeni-
aktivoituva proteiinikinaasi kinaasi (MEK) -inhibiittori PD98059, RhoA proteiinikinaasi 
(ROCK) -inhibiittori Y-27632, ja ei-lihasperäinen myosiini II (NMMII) -inhibiittori (-)-
Blebbistatin. Kyseiset inhibiittorit ovat laajalti tutkittuja, mutta niiden kriittinen 
konsentraatio, joka vaikuttaa luuytimen kantasolujen selviytymiseen, on toistaiseksi 
selvittämättä. Lisäksi inhibiittorien vaikutuksista solujen morfologiaan ja elävyyteen on 
raportoitu vähäisesti niin 2D- kuin 3D-soluviljelymalleissa. 
Neljän inhibiittorin kriittistä pistettä tutkittiin kokeellisesti tarkkailemalla solujen 
elävyyttä ja morfologiaa. Soluviljelmiä altistettiin useille inhibiittorikonsentraatioille 24 
tai 48 tunnin ajan. ). Altistumisajan jälkeen solujen morfologinen muutos kuvattiin (n=2) 
ja solujen elävyys mitattiin, niin 2D- kuin 3D-mallissakin (n=5, n=3). Soluviljelymuovia 
ja -lasia käytettiin materiaalina 2D-mallissa ja rotan kollageeni I hydrogeeliä 3D-mallissa. 
Kriittinen piste määritettiin onnistuneesti FAK-inhibiittorille sekä 2D- että 3D-mallissa 
(3.5 µM ja 5.2 µM). Konsentraatio määriteltiin myös Blebbistatinille 2D-mallissa (28.5 
µM). ROCK-inhibiittorilla ei havaittu olevan vaikutusta solujen selviytymiseen, sen 
sijaan solujen morfologia muuttui merkittävästi. Tämän perusteella kriittiseksi pisteeksi 
arvioitiin 6 µM. MEK-inhibiittori ei vaikuttanut merkittävästi elävyyteen eikä 
morfologiaan. Suoritetuilla tutkimuksilla tuotettiin uutta informaatiota kaikista 
käytetyistä inhibiittoreista. Lisäksi tulokset korreloivat työn hypoteeseja ja 
mekanotransduktiivisten signalointipolkujen hierarkiaa. 
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The transfer of physical information concerning the extracellular matrix (ECM) to cells 
via biochemical signaling is called mechanotransduction. This information, connection 
and signaling takes part in regulating cellular behaviors such as homeostasis, migration 
and differentiation. Regenerative medicine and tissue engineering (TE) applications 
could, therefore, take advantage of this interaction by altering the physical properties of 
a culturing material and, hence, manipulate stem cell behavior. However, stem cell 
differentiation activating properties of ECM remain mostly unknown. 
The mechanotransductive chain of complexes is connected to signaling pathways 
regulating cell behavior and fate. Among those signaling proteins are focal adhesion 
kinase (FAK), Rho-associated protein kinases (ROCK) and mitogen-activated protein 
kinase kinase (MEK), taking part in cytoskeletal organization, apoptosis and focal 
adhesion (FA) formation. These components regulating cell function and 
mechanotransduction can be inhibited using pharmacological, transient and reversible 
substrates. 
The inhibitors affecting mechanotransduction were chosen from several stages of various 
mechanotransductive pathways: upstream activator FAK, downstream signaling protein 
MEK and ROCK, which are also key regulators of stress fibers, and structural factor Non-
Muscle Myosin II (NMMII), controlling intracellular tension and contraction. The 
inhibitors are widely used and demonstrated in the literature. However, a critical point or 
an effective concentration at which cell survival and/or morphology is significantly 
altered has not been stated clearly. In addition, the results on the effects on viability, 
especially that of stem cells, have not been fully reported. Moreover, the morphological 
changes have not been stated for all the inhibitors. 
To date, the majority of information concerning cell behavior and signaling has been 
gathered through two-dimensional (2D) experiments. However, in living tissues, the cues 
guiding the cells and mechanotransduction are typically provided in three-dimensional 
(3D) microenvironments. The two models provide very different environments for cells 
to grow and, therefore, the information taken from 2D experiments might not be 
translatable into TE and tissue culture applications. Hereby, experiments performed in 
two different models might vary in response. 
The objectives of this study were as follows: 
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I. To determine the effects of various concentrations of inhibitors of 
mechanotransductive pathways on human bone marrow stromal cell (hBMSC) 
viability, following 24 or 48 h exposure. 
II. To determine the effects of various concentrations of inhibitors of 
mechanotransductive pathways on hBMSC morphology, following 48 h 
exposure. 
III. To compare the effects on viability and morphology between two different models 
2D and 3D. 
The aim of the objective I is to find a critical point where there is a significant change in 
the viability of the cells. This is executed by using various concentrations, selected in 
order to cover the range of reported concentrations in previous studies. The hypothesis is 
that a critical point affecting the viability of the cultures will be found for each inhibitor. 
The aim of the second objective is to use the same concentrations as in the objective I and 
to assess the morphological changes. The hypothesis of this study is that, since the 
signaling pathways are induced by mechanotransductive processes, morphological 
changes will be observed and recorded in the range of the critical point determined in 
objective I. Objective III uses two different models to study the difference between the 
dimensionality of provided mechanotransductive cues. It is hypothesized that there will 
be a difference between the two models on how the cells respond to the inhibitors and 
expected that the critical concentration is higher for the 3D model due to inhibitor 
diffusion. 
This thesis includes a literature review on stem cells, mechanotransduction and connected 
signaling pathways. In addition, a comprehensive report is given on the previous studies 
performed using the chosen inhibitors. Here, the expected responses are also stated. Next 
the materials and methods are explained and the results are given. Finally, the discussion 
explores the results and their possible causes are speculated upon. 
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2. STEM CELLS 
Stem cells are partially or completely undifferentiated cells with the capability to divide 
indefinitely and to produce progenitors with the potential to differentiate [1]. Due to these 
abilities, scientists have been highly interested to use stem cells for drug discovery, 
immunotherapy and regenerative medicine [2]. The potential of stem cells can be divided 
into three stages: totipotent, pluripotent and multipotent. Totipotent cells can divide and 
differentiate into all types of cells and can only be found in zygotes and early blastomeres. 
Pluripotent cells, such as embryonic stem cells (ESC) can generate all three germ layers 
and lineages: ectoderm, mesoderm and endoderm. These three germ layers are called 
multipotent and are more restricted in their path of differentiation. [1] 
Mesenchymal stromal cells (MSC) have mesodermal origin and are multipotent. They 
were first discovered by Friedenstein and co-workers in 1968 [3]. These cells can be 
found in several somatic tissues: bone marrow (BMSC) [3], adipose tissue (ASC) [4, 5], 
Wharton’s jelly in the umbilical cord (WJ-MSC) [6], dental tissue [7] and placenta [8], to 
name a few. Harvested MSCs have proven to be promising experimentally for TE 
applications and show potential to differentiate according to the mesodermal lineage in 
vitro. In other words, several experiments demonstrate the potential of MSCs to 
differentiate into adipogenic [9, 10], osteogenic [9, 10], myogenic [11] and chondrogenic 
[9] cells. These lineages and their tissue-specific protein expression, in addition to tissue-
specific elasticity, are illustrated in Figure 1. In addition to their differentiation potential, 
MSCs are abundantly available in several adult tissues and therefore are readily available 
and free of the ethical issues concerning ESCs. There have also been reports over MSC 
transdifferentiation into ectodermal and endodermal lineages, showing differentiation 
potential towards neuronal cells [12], hepatocytes [13] and pancreocytes [14]. These 
results are highly interesting in terms of regenerative medicine and stem cell therapy, not 
to mention tissue engineering (TE). 
Some of the activators of the signaling pathways leading to MSC differentiation remain 
uncertain. In the literature, differentiation in vitro has been simulated mostly by using 
chemical inducement but also through mechanotransduction, as chemical inducement 
might not be translatable to the in vivo situation, and could have carcinogenic effects. 
Several characteristics have been connected with fate commitment. Osteogenic 
differentiation is most commonly confirmed through the expression of runt-related 
transcription factor 2 (Runx2) [2, 5], whereas adipogenic fate commitment is 
characterized by the expression of peroxisome proliferator-activated receptor gamma 
(PPARγ) [15], among other indicators presented in Figure 1. In addition, chondrogenesis 
and myogenesis are positively characterized by the expression of SRY-related high-
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mobility group box 9 transcription factor (Sox9) [2] and myogenic differentiation (myoD) 
[4], respectively. 
 
Figure 1. Differentiation lineages of mesenchymal stem cells, their respective 
transcription factors and tissue-specific substrate elasticity. Adapted from [16]. 
The fate commitment of stem cells has also been connected to morphological changes in 
2D in vitro experiments. A flat and spread morphology is typically associated with 
osteogenic differentiation [17], whereas rounding of the cells is linked with adipogenic 
commitment [18]. As a contrast, cells committing towards neurogenic differentiation 
appear dendritic, with several protrusions [19]. In 3D, however, conflicting data exists as 
to whether these morphological indicators are directly translatable. This was 
demonstrated in a study by Clements et al. in which MSCs had a round morphology both 
in 2D and 3D hydrogel cultures (on top of and encapsulated within hydrogels), but 




Mechanotransduction is a bidirectional process of information transfer between a cell and 
its surroundings. In this process, mechanical stimuli provided by the environment are 
transferred into biochemical responses and behavioral changes within the cell. [21] The 
environment of the cell affects gene expression and subsequent behaviors via complex 
linkages, involving transmembrane proteins, numerous adaptor proteins and actin stress 
fibers. The biochemical response is delivered through several different signaling 
cascades, both in the cytosol and the nucleus. Mechanotransduction affects the cell’s 
behavior in proliferation, migration, polarity and apoptosis. In addition, 
mechanotransduction is involved in the differentiation of stem cells. [22]  
 Extracellular matrix 
ECM is the non-cellular material surrounding the cell. The ECM provides a physical 
scaffold for the cell to attach to and acts as a reservoir for biochemical cues such as growth 
factors and cytokines, which are required, for example, for homeostasis. The most 
common components of ECM are water, proteins and polysaccharides. For each tissue 
type there is a unique and specific composition and structure to the ECM that provides 
the ideal platform for tissue development and maintenance. The biophysical properties of 
ECM can vary in terms of its stiffness, elasticity and dynamic properties, such as stress 
relaxation. The dynamic properties provide the cells the possibility to remodel their 
environment either enzymatically (e.g. via matrix matalloproteinases, collagenases and 
hyaluronidase) or non-enzymatically, via hydrolysis. [23] For example, collagen and 
fibronectin, natural ECM proteins, are reported to be rearranged by the cells and usually 
align along the axis of the applied force. [24] Hence, it can be said that cells react to the 
extracellular cues received through mechanotransduction and remodel their environment. 
In addition to remodeling the matrix, cells respond to mechanotransductive information 
by adapting to their environment. The mechanical properties of the ECM regulate tissue 
functions. For example, a sudden stiffening of the ECM has been reported to cause 
malignancy in the cells. Therefore, the tension and the elasticity of ECM, or scaffolding 
matrixes in tissue engineering, have been particularly well studied. One major focus of 
recent research has been the differentiation of MSCs, solely as a response to the matrix 
stiffness, independently from growth factors. [25] 
Cells sense their ECM by applying force to it through attachments. The response is 
detected both in stress and in strain. For a rigid ECM, the response to the intracellularly 
applied force is followed by increased tension and little elasticity, which is detected by 
6 
 
the intracellular complexes, as the ECM does not yield in distance. For a softer matrix, 
the ECM deforms and therefore the intracellularly applied force responds slowly and 
elasticity is detected as a greater change in distance. [25] 
For tissue engineering and regenerative medicine purposes, more translatable in vitro 
experiments are needed before ECM stiffness properties can be used in stem cell 
therapies. Polymeric biomaterials such as natural semi-synthetic hydrogels have been 
studied to provide scaffolds that better resemble the ECM of in vivo situations. The 
stiffness and porosity of these materials can be altered by varying cross-linking density. 
[26] Hydrogels are a novel interest of study, which could enable researchers to move 
away from the dominating practice of in vitro tissue culture plastic (TCP) use in cell 
culturing experiments in 2D. Hydrogels have been used both as coating materials to 
substitute TCP and to create 3D scaffolds, in which cells can be grown in a truly 3D 
environment. Some examples of 3D hydrogel materials that have been used include 
collagen I (Col-I) [27, 28] and hyaluronic acid (HA) [29]. In addition, synthetic 
biodegradable polymers, such as poly(ethylene glycol) (PEG) [30, 31] and poly(lactic 
acid) (PLA) [32] have been used to develop tissue engineering scaffolds [33]. 
 Proteins implicated in cell-ECM interactions 
The cellular proteins that take part in ECM-cell signaling and therefore participate in 
mechanosensing, can be divided into three subgroups: integrins; adaptor proteins in FAs, 
such as vinculin and talin; and actin stress fibers. Cells are attached to the ECM through 
integrins, which in turn are attached to adaptor proteins inside the cell. The adaptor 
proteins connect with stress fibers and the signaling proteins. All components are 
essential for a fully functioning process of mechanotransduction. The interactions are 
illustrated in Figure 2 and explained in the following chapters. 
3.2.1 Integrins 
Integrins are a family of cell surface receptors, composed of two non-covalently 
associated transmembrane glycoprotein subunits, α and β. Their expression is dominant 
in animal cells [34] in charge of sensing ECM properties and translating the information 
into intracellular signals that regulate cell growth, survival, migration and gene 
expression. [25, 35] The attachment of integrins on to the ECM proteins depends on the 
ECM properties and integrins’ connection to the cytoskeleton. 
The subunits of integrins have several isoforms and their combinations vary, depending 
on the ECM protein the cell attaches to. [21] Eight different integrins are capable of 
binding to fibronectin (FN), including for example α5-β1, whereas laminin is recognized 
by five integrins, including α7-β1. There are altogether nine β and 24 α isoforms. The 
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most common β isoform is β1, which forms dimers with up to 12 α isoforms. [34] Col-I 
is recognized by α2-β1 [36, 37]. 
 
Figure 2.  A focal complex and a focal adhesion. Integrins presented in blue; adaptor 
proteins: vinculin (yellow), α-actinin, talin (green), paxillin and focal adhesion 
kinase (grey); stress fiber components: actin filaments as chains of pearls and 
myosin II in brown. Modified and reproduced with permission from ref. [38]), © 
American Physiological Society 
 
The binding of integrin to ECM ligands results in a conformational change in the 
cytoplasmic tail of the beta subunit, enabling it to bind with intracellular adaptor proteins. 
Actin subunits subsequently bind to the adaptor proteins and polymerize into stress fibers. 
[34] Clustering of integrins leads to the formation of FAs [35]. In order to function 
actively, integrins need to interact with intracellular stress fibers to bind strongly to the 
ECM. This connection is usually ensured by binding to bundles of actin filaments through 
FAs. However, the interaction with the ECM remains dynamic with a low binding 
affinity. This keeps the cells from binding too strongly to their surroundings and enables 
migration in addition to matrix remodeling. [34] 
Integrin–ECM adhesion is not only required for cell attachment; the subsequent 
mechanotransductive processes in turn influence proliferation, cytoskeletal remodeling, 
migration and differentiation. Integrins bind to the ECM proteins and provide a platform 
for the cells to execute force-dependent processes, such as cell division. The initial 
binding affinity might be low, but when force is applied, either externally or internally, 
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integrins transition to high affinity conformation. Through this binding affinity 
adaptation, integrins have a major role in sensing the stiffness of the ECM. [25] 
The role of integrin subunits in sensing matrix stiffness and differentiation was studied 
by Shih et al. by experimenting with α2 subunits. They demonstrated that cells in stiffer 
matrices had increased expression of integrin subunit α2. The group also tested the effects 
of α2 knockdown, which lead to a decrease in osteogenic expression. In addition, the 
study also reported downregulation of pFAK, pERK1 and pERK2, which demonstrates 
the connection between integrins and activated signaling proteins. The roles of ERK and 
FAK are explained later. [39] 
3.2.2 Focal adhesion complexes 
FAs are protein complexes formed on the intracellular side of the cell membrane after 
integrin attachment to the ECM. After binding to the ECM, the cytoplasmic tail of β 
subunit binds with FA proteins, including talin, tensin, paxillin and α-actinin. Some of 
these proteins then bind with vinculin, FAK, zyxin and filamin, which in turn lead to actin 
recruitment, stress fiber formation and cross-linking via α-actinin. [34] The tension in the 
integrin-ECM binding promotes the recruitment of cytoskeletal proteins to reinforce the 
integrin-actin connection [25]. There is a dynamic fluctuation in the complexes, which is 
mediated by the stiffness of the ECM. 
Focal adhesion complexes can be divided into three groups: nascent adhesions, focal 
complexes and focal adhesions. Nascent adhesions are formed immediately after integrin 
receptors engage with the ECM. They are located at the leading edge of a migrating cell 
and have a fast turnover, either diminishing or evolving into focal complexes. [40] Focal 
complexes are small circular formations, about 2 µm in diameter, which can mature into 
FAs. [24] However, the maturation requires several adjacent integrins to bind to the ECM 
and cluster, in order for the adaptor proteins to be situated close enough to one another to 
interact [26]. FAs are more mature, larger and more elongated structures, with a width of 
2µm and length of 3-10 µm [24]. 
FAs translate physical tension into intracellular biochemical signaling and are also 
involved in migration. First, extensions of the leading edge and nascent FAs are formed. 
Next, the maturation of FAs takes place and the cell body is translocated. Finally, FAs 
are disassembled and the rear of the cell retracts. [40] 
Talin also binds with integrins and cytoskeleton. It is required to reinforce the linkage and 
the assembly of FAs in response to external force. The head domain of the protein binds 
directly with the cytoplasmic tails of some α and β isoforms of integrins. In addition, talin 
binds with FAK, the importance of which is explained later. Talin not only performs as a 
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link between the cytoskeleton and the ECM, but also increases the attraction between 
ECM and integrins. [38] 
Paxillin is an adaptor protein family with three isoforms. It binds with vinculin and FAK. 
The protein also has a direct association with β1-integrin tail. Paxillin has several 
phosphorylation sites mediating cell migration and FA turnover. Its most important 
function is its implication in the efficient migration and motility of the cell. [41] 
Vinculin is an actin filament binding protein. It has an auto-inhibition system, whereby 
the head interacts with the tail and masks the binding site for actin filaments. The 
activation and therefore the exposure of the binding site occurs when it binds with other 
FA proteins, such as talin and α-actinin. [38] 
α-actinin is a homodimeric protein which crosslinks actin fibers into bundles. They are 
detected throughout the stress fibers, but they also interact with β-integrin tail and 
vinculin. They take part in controlling the stiffness of the fibers and transmit contractile 
forces. [38] 
3.2.3 Stress fibers 
The stress fibers are formed by bundles of actin filaments attached together by α-actinin 
and non-muscle myosin II (NMMII) [38]. Actin filaments form bundles of approximately 
10–30 at a time. Unlike muscle cells, other cells do not present inherent polarity of the 
filament, meaning that there is not always a plus or ‘barbed’ end, and a minus or a 
‘pointed’ end alternating in the bundle. However, the majority of motile cells have a 
uniform organization of barbed ends pointing outside. This means that the cells always 
depolymerize from the tail and polymerize at the leading edge during migration. [42] An 
actin depolymerizing factor, cofilin, attaches to the pointed end of the actin filament and 
changes its structure, leading to depolymerization of the pointed end. This also promotes 
the polymerization at the barbed end of the filament and, hence, regulates actin-based 
motility. [38] 
There are three types of stress fibers: ventral and dorsal stress fibers and transverse arcs. 
Ventral stress fibers are the most common and attach to the integrin-rich FAs, which in 
2D cultures with a high density of FAs are located at the bottom of the cell. Dorsal stress 
fibers attach to FAs at only one end, leaving the other end loose. Transverse arcs are 
located at the cell surface and connect with the dorsal loose end. [42] Given that this 
theory applies to planar 2D cell cultures, it may not directly translate into 3D systems, in 
which the cell is surrounded by a uniform matrix on all sides.  
Non-muscle myosin II (NMMII) is a motor protein attached to actin filaments. [39] It 
pulls on the filaments through crosslinking and generates contractile force through the 
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actin bundles [21, 26]. The motion is driven by hydrolysis energy of adenosine 
triphosphate (ATP). The tension and contractile forces applied by NMMII are not only 
essential for sensing matrix and shear stress, but also necessary for embryonic survival, 
cytokinesis and intracellular stiffness generation. [39] 
NMMII can be divided into three subgroups. NMMIIA is widely expressed across 
different tissues and has the highest rate of ATP hydrolysis. NMMIIB is mostly present 
in cardiac and neural tissues and has the highest adenosine diphosphate (ADP) affinity, 
giving it the longest period of binding. NMMIIC exists in epithelial cells. [39] 
 Effects of mechanotransduction on differentiation in 2D 
Matrix properties and their effects on stem cell differentiation have been studied from 
various perspectives. The most common approach is to study differentiation based on the 
size, shape and/or stiffness of the provided substrate. Through size control, the cells are 
affected by limited area available for growth, whereas through shapes and geometrical 
patterns the formation of FAs are controlled by the density and localized arrangement of 
ligands available for attachments. In 2D, the stiffness of the surface affects the cells by 
the tension created between the ECM and the cells, which also affects their morphology. 
In 3D, stiffness also appears to have an important role, though it is less consistently 
associated with specific morphologies. 
McBeath et al. studied the effect of 2D culture substrate area on hMSC morphology and 
differentiation. They found that when limited space was provided, the cells adopted a 
round shape and expressed proteins associated with adipogenesis. On the other hand, 
when space was provided in excess, the cells spread extensively and expressed proteins 
associated with osteogenesis. The study also stated that the highly-spread hMSCs showed 
more prominent stress fibers than the rounded ones. [18] 
Kilian et al. studied the effect of geometric patterns on MSCs in 2D. The area of adhesive 
“islands” on an otherwise non-adhesive substrate was kept as a constant, but the aspect 
ratios of rectangles varied. As a result, osteogenesis was more dominant as the aspect 
ratio grew. Next, a pentagonal shape was experimented with variation in curvature, 
ranging from a star shape into a flower. The flower shape drove the cells towards 
adipogenic differentiation, whereas on the star shapes the MSC preferred osteogenic fate. 
It was also noted, that on star shapes FAs and stress fibers were larger than on flower 
shapes. [43] These geometries generally correspond to the level of spreading or 
polarization of cells undergoing differentiation down the corresponding lineages. 
The effect of the stiffness of 2D culture surfaces was studied by Engler et al. hMSCs were 
plated on polyacrylamide gels varying in elasticity. Surfaces with three different elastic 
moduli were synthesized, mimicking brain tissue (0.1–1 kPa), muscle (8–17 kPa) and 
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collagenous bone (25–40 kPa). When cultured on these gels, the hMSCs showed both 
tissue-specific differentiation and morphology. [44] 
 Effects of mechanotransduction on differentiation in 3D 
The effects of cellular microenvironment on differentiation in 3D remain unclear. 
Information on cell signaling and the effects of ECM stiffness have been widely studied 
in 2D, but with 3D cues the environment is much more complex. This was demonstrated 
by Kubow et al., who showed that not all 3D model FA characteristics, such as FA protein 
composition, can be seen in 2D models [45]. To date the key factors in 3D experiments 
have been the material compliance/stiffness, ligand presentation and degradation 
properties.  
Huebsch et al. tested the effects of matrix rigidity on murine MSCs (mMSC) encapsulated 
in RGD-presenting alginate hydrogels. They detected that one week after encapsulation, 
the cells cultured in 11–30 kPa gels expressed osteogenic commitment, whereas the cells 
cultured in softer matrices (2.5–5 kPa) differentiated towards adipogenic fate. This, 
however, does not correlate directly, but is in line with the tissue specific elasticities. [46] 
Pek et al. demonstrated accordingly with PEG-silica hydrogels that hBMSC fate could be 
mediated through matrix stiffness. They also reported that the presence of RGD in the 
stiffer gels increased osteogenic commitment by 13 %. [47] 
Khetan et al. experimented on the effect of compliance and degradation on hMSC fate 
commitment. They demonstrated that when a compliant matrix was provided, the cells 
would spread and undergo osteogenic commitment, whereas in non-compliant matrix the 
cells would remain round and signs of adipogenesis would increase. However, they also 
found that the non-degradable cross-linking combined with cell spreading lead to 
adipogenesis. This indicates that the morphology or spreading of the cells is not essential 
in fate decision in 3D, whereas the degradability and compliance of the ECM are. [29] 
Jung et al. prepared composites, encapsulating not only hMSCs in four-arm PEG 
hydrogels, but also ECM proteins, Col-I, laminin-111 or FN, hereby providing hMSCs 
ECM proteins presenting ligands naturally. The differentiation experiments were coupled 
with 2D cultures provided with ECM protein coatings in addition to chemically induced 
differentiation. It was detected that, in general, adipogenesis increased in all composites. 
They also reported that, after 28 days, the Col-I composite significantly induced 
osteogenesis, adipogenesis and chondrogenesis when compared to both chemically 
induced and 2D coating cultures. The preference for adipogenesis could be explained by 
the stiffness of provided materials, a very soft modulus of only 0.9 kPa. The ECM protein-
free PEG hydrogels failed to maintain expression of both adipogenic and osteogenic 
differentiation markers after 14 days. In addition, it was reported that viability in the ECM 
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protein-free PEG hydrogel was as low as 60 %. It could therefore be argued that the 
differentiation markers in those samples might be associated with apoptosis. As a 
conclusion, 3D composites induced differentiation in all but cardiomyogenic 
differentiation, but that this was only statistically significant in Col-I composites. [30] 
Thus the experiment highlights the importance of both stiffness and the presented ligands. 
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4. SIGNALING PATHWAYS 
 Focal adhesion kinase pathway 
Focal adhesion kinase (FAK) is a tyrosine kinase located at integrin-enriched cell 
adhesion cites within FAs [48]. This protein takes part in several cellular functions 
through various signaling pathways, including migration [48, 49], cytoskeletal regulation 
[48], stem cell differentiation [16], proliferation and survival [49, 50]. The protein is 
composed of three functional domains: N-terminal 4.1 ezrin-radixin-moesin (FERM) 
domain, kinase domain and C-terminal focal adhesion targeting (FAT) domain. [48, 51] 
The structures, their targets and functions are listed in Table 1. 
The FERM domain of FAK presents a structure similar to other cytoskeletal proteins, 
including talin and ERM proteins [48, 49], but also signaling molecules, such as JAK 
family of tyrosine kinases [49]. The FERM domain also binds with the cytoplasmic tail 
of integrin β1 and various growth factor receptors [49], including platelet-derived growth 
factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) [48]. It has been 
hypothesized that the FERM domain of FAK could inhibit the activity of the FAK kinase 
domain. This has been supported by the enhanced activity of FAK kinase domain after 
the removal of FERM domain. [48, 49] 
When the kinase or catalytic domain of FAK is phosphorylated, a structure is formed 
which is recognized by several SH2 domain-containing proteins. These proteins include 
Src-family kinases (SFKs), phospholipases Cγ (PLCγ), suppressor cytokine signaling 
(SOCS), growth factor receptor-bound protein 7 (GRB7), the Shr adaptor protein, p120 
RasGAP and p85 subunit of phosphatidylinositol 3-kinase (PI3K). [48] The binding of 
FAK-Src leads to several tyrosine phosphorylations at multiple sites in FAK [48, 52, 53]. 
One phosphorylation target of the FAK-Src complex is p130Cas. The downstream 
signaling result of p130Cas phosphorylation is the increased activity of Rac, the regulator 
of membrane ruffling, lamellopodia formation and cell motility promotor [48, 51].  
FAK-Src complex also phosphorylates tyrosines in the FAT domain. The 
phosphorylation of paxillin, an FA protein, occurs through this path. The phosphorylation 
of paxillin regulates FA turnover and migration [41]. The FAT domain phosphorylation 
also binds p190 RhoGEF, a Rho-family GTPase activator. RhoA is activated by p190 
RhoGEF and, hereby, FAK has a direct link to RhoA signaling pathways. [48, 54] The 
other important protein, which binds to FAK after phosphorylation, is growth factor 




Table 1. FAK domains, targets and functions. 
Domain Targets and downstream 
effectors (if known) 
Function Reference 
FERM 
ERM proteins Activation through integrin 
contacts 
Suppression of kinase domain 
activation 









p120RasGAP Activation of Ras [48] 
GRB7 Migration [48, 51] 
p130Cas 






RhoA-ROCL pathway regulation 




- ARP2/3 complex 
Actin polymerization in the 
leading edge of a migrating cell 
[51] 
FAT 
Talin Focal adhesion activation [55] 
Paxillin 
Focal adhesion turnover  










 Ras-Raf-MEK-ERK pathway 
The Ras-Raf-MEK-ERK is a signaling cascade that transfers signals from the cell 
membrane to the nucleus [56, 57]. The pathway is implicated in cell cycle progression, 
proliferation, apoptosis [56-58] and differentiation [56, 59]. The cascade is regulated 
through several other interacting signaling pathways and is thought to have different 
effects, depending on the cell lineage [56].  
The cascade starts with the activation of Ras, a small GTP-binding protein, which is an 
upstream molecule for several signaling pathways [57]. Ras is activated upon stimulation 
of Shr-Grb-SOS complex, which is coupled after the binding of cytokines, growth factors 
or mitogens to appropriate receptors in the cell membrane. Four Ras proteins have been 
identified: Ha-Ras, N-Ras, Ki-Ras 4A and Ki-Ras 4B. It has been suggested that the 
proteins have different abilities in activating the Raf-MEK-ERK cascade. For example, 
Ki-Ras appears to be a stronger inducer than Ha-Ras. [56] 
Downstream kinase Raf is activated through a series of events, including recruitment to 
the plasma membrane through an interaction with Ras, dimerization and phosphorylation 
at several sites [57]. There are three members of the mammalian Raf gene family: A-Raf, 
B-Raf and Raf-1 (C- Raf). Ras and Src activity is required for maximal activation of A-
Raf and Raf-1, but it seems that B-Raf is not dependent on Src. In addition, it is reported 
that B-Raf is more prone to mutations that take part in human cancers than A-Raf and 
Raf-1. When it comes to the signaling cascade of Ras-Raf-MEK-ERK, B-Raf is the most 
potent in activating MEK. It has also been suggested that B-Raf might take part in Raf-1 
activation. The Raf-MEK-ERK signaling pathway is regulated positively and negatively 
by additional transduction pathways such as the Ras/PI3K/PTEN/Akt pathway. [56] 
Mitogen-activated ERK kinase (MEK), which is also known as mitogen-activated protein 
kinase kinase (MAPKK) [59], is positively induced by Raf [56, 57]. MEK1 and MEK2 
are the two recognized forms of MEK. [57] Together, they are the only dominant 
upstream activators of ERK. [56, 59] 
Extracellular signal regulated kinase (ERK), or mitogen-activated protein kinase (MAPK) 
[59] is activated by dual phosphorylation on tyrosine and threonine residues, separated 
by a glutamate residue [59]. As a result of activation, two forms of ERK are met: ERK1 
and ERK2. The difference in targets in vivo of the two molecules are yet rather poorly 
understood. However, it would seem that ERK2 drives more proliferative effects, whereas 
ERK1 has more anti-proliferative effects. [56] 
Activated ERKs affect various cellular behaviors via phosphorylation of several 
transcription factors, such as Ets-1, c-Jun, NF-κB, AP-1 and c-Myc [56]. It has been 
reported that these phosphorylated transcription factors induce the expression of genes 
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related to cell cycle progression, including Cdks, cyclins and growth factors, in addition 
to preventing apoptosis. [57] ERKs are also responsible for the activation of p90Rsk 
through phosphorylation, causing the activation of cyclic AMP-responsive element 
binding protein (CREB) [56, 57], a transcription factor which regulates the CAMP 
signaling pathway. In addition, it takes part in signal transduction induced by Ca+2, 
growth factors and stress signals. [57]  
ERK also has an effect on apoptosis by regulating post-translational phosphorylation of 
apoptotic regulatory molecules Bad, Bim, Mcl-1, caspase 9 and Bcl-2. [56] The signaling 
pathway can inactivate Bad by phosphorylation at residue S112, which enables Bcl-2 to 
form homodimers and leads to an anti-apoptotic response. An anti-apoptotic response is 
also achieved by phosphorylation of Mcl-1. On the other hand, through phosphorylation 
of the pro-apoptotic Bim, apoptosis is inhibited, as the protein is dissociated from Bcl-2 
and Mcl-1 and targeted to proteasomes. Hereby Bcl-2 and Mcl-1 bind with Bax, 
preventing it from forming homodimers and inhibiting apoptosis. 
It has been suggested that ERK regulates Runx2-mediated gene transcription alongside 
JNK.  This is explained by the signaling coupling with transcriptional coactivator with 
PDZ-binding motif (TAZ) and Yes associated protein (YAP), which are stimulated by 
stiff ECM, leading to their co-localization to the nucleus and subsequent osteogenic 
differentiation. TAZ and YAP are effector proteins in the Hippo signaling pathway, which 
affects proliferation, tumorigenesis and stem cell self-renewal [58]. In addition, studies 
have shown that ERK phosphorylates PPARγ and therefore restricts adipogenesis [59].  
Abnormal activation of Raf-MEK-ERK has been associated with some human cancers. 
This is due to mutations at upstream membrane receptors Ras and B-Raf or in the 
interacting transduction pathways (eg. Ras/PI3K/PTEN/Akt) which regulate Raf activity. 
According to the literature, the malfunction of Raf-MEK-ERK pathway can have various 
affects depending on the cell lineages. For example, in hematopoietic cancers, the 
signaling pathway promotes proliferation, but it is inhibited in several prostate cancer 
cases. The varying effects could be explained with coupling protein mutations such as 
PTEN and p53 pathway. Abnormal function of the signaling pathway has also been 
reported to cause drug resistance. [56] 
 RhoA-ROCK pathway 
RhoA is part of Rho family of small GTPases, which is activated through G protein-
coupled receptors (GPCR). Activators, such as lysophosphatidic acid (LPA) or 
sphingosine-1 phosphatase (S1P), stimulate guanine nucleotide exchange factor (GEF), 
which leads to an active GTP-bound Rho. [42, 60].  
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RhoA activates Rho-associated protein kinases (ROCKs) through Rho-binding domain 
(RBD) [60, 61]. The kinases can also be activated by arachidonic acid and caspase-3 [61]. 
ROCKs have been found to be involved in several cellular responses, such as cellular 
growth, migration, metabolism and apoptosis, through actin cytoskeleton assembly, 
disassembly and contraction [60, 61]. ROCKs are naturally inhibited in the cells by RhoE, 
Gem and Rad [42]. 
The ROCK family can be divided into two subgroups: ROCK1/ROCKbeta and 
ROCK2/ROCKalpha [61] ROCK1 is reported to be ubiquitous, but with higher 
expression levels in non-neuronal tissues such as liver, lungs and testis. ROCK2 is also 
widely expressed, but occurs at higher levels in cardiac, brain [60] and muscle tissues 
[61]. 
The regulation of actin cytoskeleton by ROCKs takes place through phosphorylation of 
myosin light chain (MLC) phosphatases. ROCKs phosphorylate myosin phosphatase-
targeting subunit 1 (MYPT1), which decreases the activity of MLC phosphatases and 
increases the amount of phosphorylated MLC. This leads to interactions between myosin 
and F-actin, causing cell contraction and FA reinforcement. [61]  
Actin stress fiber formation is also controlled through LIM kinases (LIMK). Cofilin is an 
actin binding and actin depolymerizing protein, which controls the turnover of actin 
filaments. ROCK1 phosphorylates LIMK1 and LIMK2, which in turn phosphorylate 
cofilin [60, 61], inhibiting its action and therefore increasing the number of stress fibers. 
ROCK2 is necessary for phagocytosis and cell contraction. It phosphorylates ezrin-
radixin-moesin (ERM) proteins, which leads to the disruption of a head-to-tail association 
of the proteins and causes actin cytoskeletal reorganization and crosslinking with 
transmembrane proteins. [61] 
In the literature, there are several references to ROCKs being the dominant regulator of 
cell polarity. ROCKs impair the formation of protrusions and extensions of the membrane 
all but in the leading edge of the cell. This has been explained by the phosphorylation of 
PAR3, which is a component of the PAR polarity complex. The phosphorylation by 
ROCKs indirectly prevents the formation of extensions by Rac. [61] 
The abnormal behavior of RhoA-ROCK signaling has been connected to cardiovascular 
diseases. In the vascular wall, ROCK mediates smooth muscle contraction through actin 
cytoskeletal organization, cell adhesion and motility. Therefore, it can be said that 
increased ROCK activity leads to tumor metastasis and overexpression of activated 




 FAK inhibitor - PF-562271 
In the literature, several molecules have been reported to inhibit FAK. One of these is PF-
562271, which shows effective inhibition of the kinase activity of FAK with a high degree 
of selectivity. PF-562271 shows significant promise in tumor therapy. The inhibitor has 
been reported to cause tumor stasis in mouse models of prostate, breast, colon, lung, 
glioblastoma and pancreatic cancers. The tumors show an increase in apoptotic cells. [54] 
In 2012, PF-562271 was the first FAK inhibitor to have been tested in phase I clinical 
trials. [62] 
By description of the manufacturer and other reports, PF-562271 is a potent ATP-
competitive reversible inhibitor of FAK and Pyk2, achieving an IC50 of 1.5 nM and 13–
14 nM, respectively, in cell-free studies. [63-65] IC50 is a concentration of an inhibitor 
causing 50 % of the maximum effect. However, when tested in a cell culture environment, 
the IC50 values range from 0.277–49.89 µM, depending on the cell line. [63] hMSCs 
were not listed among the tested cell lines.  
PF-562271 treatment abrogates proliferation and decreases viability. Roberts et al. 
exposed human prostate cancer cell line PC3-M to PF-562271 for 48 hours and detected 
significant G1 cell cycle inhibition at a concentration of 3.3 µM [64]. On the other hand, 
Yoon et al. applied several concentrations of PF-562271 to ovarian clear cell 
adenocarcinoma cell line OCCC and reported 50 % loss of the cultures lowest at 3–6 µM 
and highest at 6–12 µM concentrations. [66] It should be noted, that the cells were 
induced with a copy number gain of FAK gene to study overexpression. This disturbance 
both in proliferation and viability could be explained by a lack of FAs, as the key mediator 
in assembling was inhibited. The decrease in FAs both disrupts the necessary tension 
needed for cell growth in cell cycle and in cytokinesis. Moreover, without FAs the 
anchorage-dependent cells would die due to anoikis. The details of some 2D in vitro 
studies of PF-562271 are listed in Table 2. 
As PF-567221 has been used in clinical trials, several studies have been implemented in 
vivo instead of in vitro. Roberts et al. provided several different doses of the inhibitor to 
human glioblastoma-bearing mice. They reported an IC50 of 93 ng/mL. In addition, the 
study described a significant increase in apoptosis of lung cancer tumor xenografts after 
treatment with 25 mg/kg twice, daily, for three days. [64] Sun et al. reported tumor 
suppression both in local implants and xenograft models after being given five doses per 
week for up to two weeks in mice. [65] It is argued that the primary mechanism of tumor 
suppression with PF-562271 is anoikis. Bleomycin-induced lung fibrosis mice were 
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treated with PF-562271 (15 mg/kg, twice daily) and showed similar structure to the 
control lungs with little tissue fibrosis or abnormality in pulmonary structure after 21 
days. The abrogation of lung fibrosis achieved in a comparative test with small interfering 
RNA (siRNA)-mediated FAK knockdown. [62] Some in vivo studies of PF-562271 are 
listed in Table 3. 
Table 2. 2D in vitro studies of FAK inhibitor PF-562271. 
Cell type Concentrations Time-point Outcomes Reference 
PC3-M 3.3 µM 48 h 
G1 cell cycle 
inhibition 
[64] 
OCCCs 0–50 µM 72 h 
50 % decrease in 
viability at 3–6 µM 
or 6–12 µM  
[66] 
HUVECs 10 µM 30 min Decrease of pFAK [67] 
 
The probable responses to inhibitor exposure can also be predicted based on other FAK-
related experiments, such as those involving genetically modified mice or the use of 
siRNA. The role of FAK’s kinase domain was studied by injecting HUVECs with FAT-
containing C-terminus of FAK, without the kinase domain. The FAT sequence was 
delivered with GST-beads and performed through competitive binding, inhibiting FAK 
entry into FAs. It was detected that the endogenous FAK in FAs decreased, but did not 
affect the localization of other FA proteins such as vinculin and talin. Therefore, it was 
suggested that FAK might work as a signaling protein due to the formation of FAs, rather 
than performing as a mediator in their assembly. However, it was recognized that the 
inhibition of FAK prevents cell cycle progression and that FAK supports the survival of 
adherent cells. [68] 
Table 3. In vivo studies of PF-562271. 
Cell type Concentrations Time-point Outcomes Reference 
Tumor 
xenografts 








25 mg/kg,  
5 doses a week 
2 weeks 
Tumor suppression, 















Salaznyk et al. transfected hBMSCs with FAK siRNA. After eight days of culture, the 
relative Runx2 phosphorylation was quantified. In osteogenic medium (OM)-treated 
cultures there was a significant difference between the control and siRNA-treated cells, 
showing decrease of Runx2. The same was detected after the tissue culturing plastic was 
coated with either FN, Col-I or vitronectin. Moreover, the phosphorylation of ERK 
decreased after FAK siRNA treatment. The siRNA treatment blocked Osterix 
transcriptional activity and prevented osteogenic differentiation. These results indicate 
that FAK has a role in osteogenic differentiation. [69]  
Mouse embryos with either wild-type FAK+/+, FAK+/- or FAK-/- expression were 
compared in terms of size and other visible changes after E8.0 (embryos aged 8.0 days 
old). The embryos with FAK+/- and FAK-/- expression appeared smaller in size than 
those with FAK+/+ expression. The FAK-/- embryos did not survive beyond day E9.0, 
and after E11 the FAK+/- became indistinguishable from those with FAK+/+. The 
knockout cells also showed multiple and fragmented nuclei. However, there was no 
evidence of changes in actin expression. In addition, the same group studied the 
dependence between FAK and p53. After seven days’ growth, FAK-/- embryos showed 
stronger expression of p53 than the two other genotypes. Moreover, the knockout of p53 
increased the proliferation of FAK-/- significantly. The relation was also tested with 
human fibroblasts and it was detected that after short hairpin RNA (shRNA)-treatment 
targeting FAK, the expression of p53 increased. Therefore, it was concluded that FAK 
controls human fibroblast proliferation and p53-dependent apoptosis. [53] 
Castillo et al. compared two types of primary immortalized osteoblastic clonal lines 
expressing either wild type FAK or FAK-/- mutation. No difference in actin cytoskeleton 
was detected but the mean number of FAs per cell area was significantly lower in FAK-
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 MEK inhibitor - PD98059 
The targeting of MEK is advantageous as it is the upstream dominant kinase of ERK. 
Hence, the inhibition of MEK blocks several downstream signaling pathways of ERK, 
preventing the activation of several transcription factors. In other words, MEK serves as 
a bottleneck in cell signaling which, when interrupted, can have a knock-on effect on 
multiple pathways. [56] In the literature, many MEK inhibitors are mentioned and in the 
present study PD98059 was used. The manufacturer reports an IC50 of 2 µM in a cell-
free assay, but presents several studies using concentrations in the range of 2–100 µM. 
PD98059 inhibits MEK activation of ERK1 and ERK2, but does not interrupt ERK 
directly. It should be noted that the inhibitor does not affect Raf-1 phosphorylated MEK1. 
[71] Successful ERK inhibition has not been reported. As there are two known ERK 
molecules, ERK1 and ERK2, with indication to different targets, specific ERK inhibitors 
could be useful in the future, when it comes to treatment of diseases. [56] 
Roberts and Der discussed the possibilities of MEK inhibitors in cancer treatment in 2007 
and suggested that the potential is great due to the signaling cascade’s major role in a 
normal cell’s proliferation, survival and differentiation [72]. However, in the literature 
there is very little reported on experiments concerning the viability or morphological 
changes of PD98059 treated cells. The differentiation potential of MEK inhibitor-treated 
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cells, on the other hand, is quite well demonstrated. Several studies concerning the 
differentiation of PD98059-treated cells are summarized in Table 5. 
Jaiswal et al. cultured hBMSCs in 2D in OM conditions, resulting in an even ratio 
between osteogenesis and adipogenesis. When a culture was exposed to 50 µM of the 
inhibitor, adipogenesis increased in a dose-dependent manner after 16 days. The results 
were confirmed both histologically and biochemically. Hereby, it was concluded that 
ERK has an important role in osteogenesis. [59] Concurring results were presented by 
Salaznyk et al. However, the group used ECM protein-coated culture surfaces and 
demonstrated significant decrease in the expression of osteogenesis indicator Runx2 after 
8 days. [69] Liu et al. demonstrated that these results also applied to hASCs, the alkaline 
phosphatase activity of which decreased after exposure to 50 µM of the inhibitor after 14 
days. However, they did not manage to show adipogenic commitment, except when OM 
was provided with Dex. [73] 
Table 5. Summary of studies on differentiation with PD98059. 
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Ward et al. investigated an additional factor by applying mechanical strain to Col-I-coated 
culture surfaces. They also reported on other differentiation pathways. Upon application 
of strain, the BMSCs showed increased osteogenic expression, whereas adipogenesis, 
chondrogenesis and neurogenesis decreased and myogenesis fluctuated over several time-
points up to five days. A concentration of 50 µM of MEK inhibitor had the opposite effect 
and reduced calcium phosphate levels, an indicator of osteogenesis, and induced non-
osteogenic expression, such as adipogenesis, neurogenesis and myogenesis. [74] 
The 2D studies presented so far contrast with the results by Lund et al. under 3D 
conditions. In this study, MSCs were cultured in Col-I hydrogels and conditioning with 
50 µM inhibitor enhanced the expression of osteogenic markers significantly when 
measured after 7 days, with a concurrent lack of adipogenic marker expression. [75]  
There have been several studies of the inhibitors’ effects on cell cycle and proliferation 
from previous years. Liu et al. exposed human osteosarcoma cells to the inhibitor at 50 
µM, which induced an anti-proliferative effect after 24 hours. This was confirmed by 
following G1 and G2/M phase arrest through both protein and mRNA expression levels 
of G1 phase. [73] The results were aligned with a separate study from Cui et al. with 
human dermal fibroblasts. They reported decrease in proliferation after four days. [76] 
Studies on proliferation involving PD98059 are summarized in Table 6. 
Table 6. Summary of studies on proliferation with PD98059 















Based on previous studies presented here, two conclusions can be drawn. First, the 
inhibitor concentrations used vary very little and therefore it would be useful to study a 
wider range of concentrations. In the literature, it was mentioned that a concentration of 
10 µM decreased the phosphorylation of ERK after 30 min, and therefore lower 
concentrations should also be experimented on. [67] Second, most of the previous studies 
concentrate on the changes in differentiation behavior after inhibitor exposure. ERK has, 
however, been shown to be affected by integrin activity and mechanotransduction. For 
both of these reasons, the effects on viability and morphology should be studied and a 
broader range of concentrations should be used. 
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 ROCK inhibitor - Y-27632 
According to Amano et al., inhibiting ROCK results in three visible changes that can be 
detected in cell cultures: disturbed stress fiber formation, lack of cell polarization and 
abnormalities in cytokinesis. As ROCK is responsible for the maintenance of stress fibers 
and contractility via MLC phosphorylation and LIMK activation, the use of inhibitors is 
expected to lead to disorder of stress fibers. The polarity of a cell is essential for migration, 
and since ROCK controls the polarization and leaves a cell with only one leading edge, 
inhibition would most likely cause random protrusion formation, leading to multiple 
leading edges. Tension and contraction are both key elements for cell division, especially 
in cytokinesis, when a cell is divided into two daughter cells by an actomyosin-based 
contractile ring, the assembly, stability and disassembly of the cleavage furrow. The 
inhibition does not, however, arrest cytokinesis, but causes delays in division and 
abnormalities in cultured cells. [61] 
There are two reported ROCK inhibitors in the literature, Y-27632 and Fasudil, but on 
several occasions, the overexpression of dominant negative mutants of ROCKs has also 
been used as an approach to inhibit the pathway. These inhibition tactics for ROCK have 
resulted in loss of stress fibers and focal adhesion complexes. [61, 77] In the present 
study, Y-27632 was chosen as the inhibitor of ROCK and will be later on referred to as 
ROCK inhibitor. The manufacturer describes the inhibitor as a selective ROCK1 inhibitor 
with the potential to also inhibit ROCK2. However, no IC50 is given. Instead, the binding 
affinity (Ki) of the ROCK1 and ROCK2 inhibitors are stated as being 140 and 300 nM, 
respectively. [78] 
There are several reports on morphological changes and protrusion formations in cell 
cultures after Y-27632 treatment. Ishizaki et al. cultured Swiss 3T3 cells with 10 µM of 
the inhibitor and detected actin fiber dissolution after 30 min of exposure. After 24 hours 
of treatment, thin F-actin bundles reappeared, but thin processes were visible in the 
cultures. The processes were compared to long neurite-like processes, composed of 
microtubules and intermediate filaments. The cause of process growth was explained by 
the loss of tension in ROCK-mediated contractile actomyosin filaments. [79] Worthylake 
et al. treated human primary monocytes with several concentrations of the inhibitor and 
reported morphological abnormalities in a dose-dependent manner. The cells showed 
detectable tails with doses as low as 1 µM. The tails were more apparent and longer when 
the concentration was increased. [80] Images presented in the report of Arnsdorf et al. 
show protrusion or tail formation compared to the control, even though this is not 
discussed in the study. The results were achieved with 10 µM treated mouse mesenchymal 
progenitor cells after one hour. The study does, however describe the cells as being 
stellate, with ruffled edges. [81] In contradiction, McBeath et al. reported no change in 
the morphology of 10 µM-treated hMSCs. [18]. Novozhilova et al. exposed human neural 
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precursor cells to 5 µM of the inhibitor and recorded their in-growth to a rat brain slice 
tissue over two weeks. By morphology, the neurite length was longer and elongated 
processes were detected. In addition, the cells’ somata were elongated. [82] Maldonado 
exposed human induced pluripotent stem cells (hiPSC) to several concentrations of the 
inhibitor up to 50 µM for 36 hours. The cells responded by increasing in cell area, but by 
decreasing in actin intensity when the concentration was increased. [83] In Table 7, the 
experiments are summarized in more detail. 
Table 7. Summary of morphological studies in 2D using Y-27632. 
Cell type Concentrations Time-point Outcomes Reference 
Swiss 3T3 10 µM 




Thin processes, thin actin 




1–10 µM 45 min 
Detectable tail starting from 
1 µM, increased in length 
and numbers with increasing 
concentration 
[80] 
mMPC 10 µM 1 h 
Lack of actin fibril 







5 µM 2 week 
Migration into the explant, 
two-fold increase, elongated 
processes, elongated cell 
somata 
[82] 
hIPSC 0–50 µM 36 h 
Increase in cell area, 
decrease in actin intensity 
[83] 
 
Ishizaki et al. also studied the effect of Y-27632 on G1-S transition and cytokinesis. By 
exposing Swiss 3T3 cells to 10 µM and 100 µM of the inhibitor, G1-S transition was 
delayed by one and four hours, respectively. This indicates that ROCK may not be a 
critical component in the transition, but causes delays when its action is interrupted. The 
role of ROCK in cytokinesis was also tested on HeLA cells after four hours of exposure. 
Inhibition of cytokinesis was detected at 30 µM, but this was not statistically significant 
below a concentration of 100 µM. This further indicates that ROCK might not have a key 
role in proliferation. On the other hand, a compensatory mechanism could take over in 
the absence of ROCK. One possible effector could be citron kinase, which is also present 
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in the cleavage furrow during cytokinesis. This kinase is more resistant to Y-27632. [79] 
Wu et al. exposed marmoset iPSCs to several concentrations of the inhibitor and followed 
colony growth after seven days. In the study, growth was detected at concentrations up to 
20 µM. The colony growth was, however, significant only up to 10 µM. In addition, 10 
µM exposure decreased levels of caspase-3, a key factor in cell apoptosis, significantly 
after three days. Moreover, levels of Bax and Bcl-2 remained the same. The results 
suggest that the inhibitor could increase the survival rate of stem cells by preventing 
caspase-3 mediated apoptosis. [84] The experiments are summarized for comparison in 
Table 8. 
Table 8. Summary on proliferation and viability studies performed in 2D using Y-27632. 





10 µM - 1 h delay in G1-S transition 
[79] 
 
100 µM - 4 h delay in G1-S transition 
HeLa cells 10, 30, 100 
µM 
4 h Inhibition of cytokinesis 




5, 10, 20 µM 7 d Colony percentage increased 
significantly at 5–10 µM [84] 
 
There are several reports on stem cell fate abrogation due to the use of Y-27632 in 2D 
models. McBeath et al. detected that 10 µM of the inhibitor was enough to abrogate 
constitutively active RhoA-induced osteogenesis in hMSCs after one week [18]. Arnsdorf 
et al. cultured mouse mesenchymal progenitor cells on fibronectin-coated glass slides. In 
comparison to the control, the cells exposed to 10 µM decreased in Runx2 expression by 
three-fold after one hour. Moreover, Sox9 expression increased twofold, which indicates 
that by limiting tension through inhibition, cells might derive towards chondrogenic fate. 
[81] Geometrical cues were provided to hMSCs, varying in curvature of a pentagon, by 
Kilian et al. When the cultures were exposed to 2 µM of the inhibitor, a star-shape induced 
osteogenesis was abrogated and all shapes were derived towards adipogenic fate, 
independently of the shape. [43] Shih et al. cultured hBMSCs with 5 µM of the inhibitor. 
They followed osteogenic expression over a three-week period. Type I collagen and 
osteocalcin expression decreased significantly after two weeks and even more after three 
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weeks. The study also tested the effect of inhibition on other signaling proteins and 
recorded downregulation of pFAK and pERK1/2 after three days of exposure. [85] 
A further study by Hwang et al. suggested that Rho activation is important for stiff matrix-
induced osteogenic activation. hMSCs were plated on acrylamide and bis-acrylamide 
mixture hydrogels with varying stiffnesses. A stiffness of 4.47 kPa induced osteogenic 
differentiation in the controls. Nevertheless, as the cultures were treated with 50 µM of 
Y-26732, a decrease in osteogenic gene expression was detected. In addition, TAZ 
nuclear localization was abrogated, along with targeting gene expression after 12 hours 
of treatment. [58] The results indicate that ROCK is an important mediator of stiff matrix-
induced osteogenesis. The studies on differentiation performed in 2D with Y-27632 are 
summarized in Table 9. 
Table 9. Summary of differentiation studies performed in 2D with Y-27632. 
Cell type Model Concentrations Time-
point 
Outcomes Reference 








mMPC 2D 10 µM 1 h 
Runx2 expression 
decreased threefold, 





































Several studies have been performed with Y-27632 in 3D models. Maharam et al. cultured 
mouse MSCs in a 3D environment in the form of a silk fiber scaffold. In this scaffold, the 
control cells adopted an elongated morphology along the fibers and expressed tenogenic 
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differentiation. To study the role of ROCK in this setup, the culture was treated with 10 
µM of the inhibitor for seven days. The results showed a decrease in elongated 
morphology and tenogenic mRNA expression, including genes such as Scx, Col1a1, 
Nfatc4 and Nst. [86] On the other hand, Khetan et al. cultured hMSCs encapsulated in 
methacrylate malemide hyalyronic acid (MeMaHA) hydrogels. The cells were exposed 
to 10 µM of Y-27632, daily. After seven days, cells exposed to the inhibitor had deformed 
the matrix less than the control, but the spreading was visibly similar. However, the 
cytoskeletal organization had decreased. After 14 days, the cells showed no change in 
morphology when compared with the control, even though minimal actin expression was 
detected. Adipogenic differentiation was detected and extensive lipid droplet formation 
was visible. [29] The reported studies with Y-27632 in 3D are summarized for 
comparison in Table 10. 
Table 10. Summary of 3D studies performed with Y-27632. 






10 µM 1 h 
Long protrusions compared 
to the control 
[27] 
hMSC 
10 µM, daily 
doses 
7 days 




Decrease in gel deformation, 
adipogenesis, lipid droplet 
formation, minimal actin 
expression 
mMSC 10 µM 7 days 




 Non-muscle myosin II inhibitor - (-)-Blebbistatin 
When compared to the other used inhibitors, Blebbistatin, a NMMII inhibitor, has only 
recently been reported in the literature. The role of NMMII has been widely discussed 
and reviewed, although Blebbistatin has received less attention. “(-)-Blebbistatin” is 
presented as an inhibitor for NMMII ATPase by the manufacturer, with an IC50 of 2 µM 
in cell-free assays. The usage of the inhibitor should inhibit contraction, but not disable 
mitosis or contractile ring assembly. It can, nevertheless, inhibit cytokinesis. [87] 
Reported studies often use Blebbistatin in addition to F-actin disrupting inhibitors. 
Several studies can be found investigating its effects on both morphology and 
differentiation, but not viability. 
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The morphology of Blebbistatin-treated cells are reported to change drastically. Arnsdorf 
et al. exposed mMSCs with 50 µM of the inhibitor, leading to stellate cells with ruffled 
edges. They also described lack of fibril organization. [81] This was confirmed by Ngo 
et al. by using several concentrations up to 50 µM. After 48 hours of exposure to 50 µM 
the hBMSCs showed a complete change in morphology by rounding. They also reported 
reduced cell area and total contractility arrest at 10 and 50 µM after 24 hours, respectively. 
[88] The reduction in spreading and increasing in roundness was also demonstrated by 
Caliari et al. with 50 µM conditioning of hBMSCs after seven days. [89] However, 
Sharman et al. conditioned WJ-MSCs using only 5 µM Blebbistatin, causing major 
changes in cell size and spreading. This major change after only exposure to such a low 
concentration could be due to the conditioning time of two passages. [90] The changes in 
morphology seem to be in alignment between 2D and 3D culture environments. This was 
confirmed by Maharam et al. in mMSC cultured in silk scaffolds. The cells showed a 
decrease in elongation after exposure to 50 µM of the inhibitor for seven days. [86] 
Morphology studies involving Blebbistatin are summarized in Table 11 for comparison. 
In addition to morphology, the proliferation of a cell seems to be affected by Blebbistatin. 
The inhibitor causes a decrease in contraction and therefore disrupts cytokinesis. This can 
be seen in the form of multi-nucleated cells, as demonstrated by Straight et al. in HeLa 
cells, in a dose-dependent manner, with concentrations in the range of 0–150 µM [91].  
Sharman et al. reported the slowing down of proliferation of WJ-MSCs after conditioning 
using 2.5–10 µM Blebbistatin, for several passages. A concentration of 10 µM resulted 
in almost total arrest of proliferation. This was confirmed by following the change in 
population doubling time. [90] The studies are listed in Table 12 for comparison. 
The loss of tension and contraction in the cells affects the fate commitment. A 
concentration of 50 µM inhibitor abrogated RhoA- [18] and stiffness- [44] induced 
osteogenesis, after seven days and 48 hours, respectively. The stiffness variation with 
polyacrylamide gels caused Blebbistatin not only to halt fate commitment towards 
osteogenic lineage but also myogenesis and neurogenesis. [44] Arnsdorf et al. 
conditioned mMSC with 50 µM of Blebbistatin and flow, leading to a threefold increase 
in Sox9 expression, a marker of chondrogenesis [81]. Interestingly, geometrically 
induced osteogenesis was halted by only 1 µM Blebbistatin in hMSCs. Moreover this 
combination led to adipogenesis. [43] This result was supported by Khetan et al. with 3D 
MeMaHa hydrogel cultures. After 14 days of hMSC culturing with 50 µM of the inhibitor, 
cellular traction decreased, osteogenesis was reduced and adipogenesis was increased. 





Table 11. Summary of studies on morphology performed with Blebbistatin. 






10, 50 µM 24 h 




50 µM 48 h 
Complete 
morphological change, 
no change in viability 
mMSC 2D 50 µM 1 week 





2D 5 µM 
2 
passages 
Major changes in 
morphology, cell size 
increased 
[90] 
mMSC 3D 50 µM 7 days 




NMMII has only been described as a downstream effector in mechanotransduction. 
However, its inhibition could have effects on upstream signaling proteins, leading to 
several other effects. Ngo et al. exposed hBMSCs to 5 or 10 µM of the inhibitor 
chronically through several passages. As a result, the expression of NMMIIA/B were both 
increased. They therefore concluded that either the concentrations used were too low or 
that secondary mechanisms take effect after longer exposure times. [88] Caliari et al. used 
50 µM Blebbistatin for seven days and measured the expression of ROCK and pERK1/2. 
Both were decreased, suggesting the loss in contraction and tension inside the cell 
regulates the expression of upstream proteins. [89] 
Table 12. Summary of proliferation assays with Blebbistatin. 
Cell type Model Concentrations  Time-
point 
Outcomes Reference 
HeLa 2D 0–150 µM N/A 
Multi-nucleated cells 
increased in DDM 
[91] 








Table 13. Summary of differentiation assays with Blebbistatin. 
Cell type Model Concentrations  Time-
point 
Outcomes Reference 







































Based on the results found in the literature it can be expected that the morphology of the 
cells will change, at least with a concentration of 50 µM. In addition, the proliferation 
may be affected and multi-nucleated cells should be visible in high concentration cultures. 
The viability experiments in the present study should provide new information, as very 
little has been described in previous studies. It could be speculated that as the tension and 
contractility is lost in the cells, the rounding will lead to the decrease in FAs and might 
therefore lead to anoikis. 
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6. MATERIALS AND METHODS 
 Cell culture 
Primary human bone marrow stromal cells (hBMSC) from an anonymous female donor 
(referred to as “5/16”) born in 1929 (aged 87 at the time of harvesting) were obtained 
through a medical operation performed at Tampere University Hospital. The donor 
weighed 74 kg and was 160 cm tall, with no history of osteoporosis or diabetes type I or 
II. The cells were verified by fluorescence-activated cell sorting and showed the 
propensity to undergo both osteogenic and adipogenic differentiation. Cells were thawed 
at passage four (P4) and seeded for experiments at P5, with the exception of standard 
curves for the metabolic assay, which were seeded at P6. Prior to experimentation, cells 
were cultured in basic medium (BM), consisting of minimum essential medium alpha 
(MEM α, Gibco, Thermo Fisher Scientific) supplemented with 5 % human serum (HS, 
Lonza/BioWhittaker) and 1% penicillin-streptomycin (10.000 U Penicillin/ml, 10.000 U 
Streptomycin/ml, Lonza/BioWittaker). During cell maintenance, but not during 
experimentation, BM was supplemented with 0.005 % human fibroblast growth factor-2 
(hFGF-2, Miltenyi Biotec), in order to maintain the multipotency of the hBMSC. The 
cells were maintained at 37 °C, 5 % CO2 and 95 % relative humidity.  
 Immunocytochemistry 
Samples were fixed with 0.2 % Triton-X-pFA for 10 min and were then washed with 
Dulbecco's phosphate-buffered saline (D-PBS, Gibco, Thermo Fisher Scientific). Fixed 
samples were then treated with a blocking agent consisting of 1 % BSA in D-PBS and 
incubated for 1 h at 4 °C. The primary monoclonal antibody, rabbit anti-vinculin 
(Invitrogen, Thermo Fisher Scientific) was diluted in blocking solution (1:100), applied 
to the samples and incubated overnight at 4 °C. After four washes with D-PBS, the 
secondary antibody, Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen, Thermo Fisher 
Scientific), was diluted in blocking solution (1:800). Phalloidin-tetramethylrhodamine B 
isothiocyanate (phalloidin-TRITC, Sigma-Adrich) was added to the same solution 
(1:500) and the samples were incubated for one hour. The samples were washed three 
times with 0.5 mL of D-PBS. Next, 4',6-diamidino-2-phenylindole (DAPI) was diluted in 






 Microscopy and image processing 
Bright field images were acquired using a Nikon eclipse TE2000-S light microscope with 
20X air objectives. 
Immunostained fluorescent imaging was performed using a Zeiss Axio Scope.A1 with 
63X oil immerse objective. Filters of 395 nm, 495 nm and 560 nm were used to visualize 
DAPI, vinculin and phalloidin-TRITC, respectively.  
Confocal imaging was executed with a Zeiss LSM700 laser scanning confocal 
microscope with 40X air objective. DAPI, vinculin and phalloidin-TRITC were 
visualized using solid state diode lasers: 405 nm, 488 nm, and 555 nm, respectively. 
The fluorescence microscope images were edited with Adobe Photoshop CS4. The black 
and white images obtained through microscopy were colored and three images from 
different filters were stacked. The confocal z-plane images were stacked using ImageJ. 
 Experiments in 2D 
6.4.1 Viability and proliferation 
A range of inhibitor concentrations of interest was determined, based on the literature, 
and covering concentrations above and below the reported IC50 value. In the first round 
of experiments, a two-fold dilution series was performed on each inhibitor to achieve 
eight concentrations (n=5). In the second round, concentrations were prepared at specific 
intervals, rather than through serial dilutions. Since the inhibitors were supplied in a 
dimethyl sulfoxide (DMSO) solution in order to solubilize them, experiments included 
two controls: DMSO+ and DMSO- (containing only BM without growth factors). The 
concentration of DMSO (Sigma-Aldrich) was set to a constant 1.28 % throughout the 
experiment for all inhibitors and samples, excluding the DMSO- control and several 
samples in which the inhibitor concentration exceeded 100 µM. The inhibitors, all 
obtained from Selleckchem, were: PD98059 (MEK inhibitor), Y-27632 (ROCK 
inhibitor), (-)-Blebbistatin (NMMII inhibitor) and PF-562271 (FAK inhibitor). Inhibitors 






Table 14. Inhibitor concentrations used in the 1st and 2nd rounds of 2D viability and 
proliferation experiments. 
Inhibitor Concentrations (µM) 
FAK 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8 
MEK 
1st 0.5, 1, 2, 4, 8, 16, 32, 64 
2nd 5, 10, 20, 30, 40, 50, 60, 70 
ROCK 
1st 0.5, 1, 2, 4, 8, 16, 32, 64 
2nd 20, 30, 40, 50, 60, 70, 80, 90 
Blebbistatin 
1st 0.5, 1, 2, 4, 8, 16, 32, 64 
2nd 20, 30, 40, 50, 60, 70, 80, 90 
 
Cells were plated in a 96 well plate at a concentration of 16,600 cells/cm2, and cultured 
for 24 hours, prior to inhibitor exposure, followed by a further 24 or 48 hours of exposure. 
At each time-point, the inhibitor-containing medium was removed and cultures were 
treated with Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Inc.) diluted 
1:10 in D-PBS and incubated for 3 h at 37 °C and 5% CO2. CCK-8 is a colorimetric assay 
that uses water-soluble tetrazolium salt 8 (WST-8) to measure the mitochrondrial 
metabolic activity of a cell, turning from a pale pink to a measurable yellowish hue upon 
metabolism. After incubation, absorbance at 450 nm was measured using a plate reader 
(Viktor 1429 Multilabel Counter). Every experiment was run in parallel with five fresh 
standards prepared in two-fold dilutions of cell concentration (n = 5), which were used to 
form a standard curve in order to extrapolate the viable cell count. 
6.4.2 Morphology 
For the 2D morphology assessment, cells were plated on a 24 well plate on sterilized glass 
coverslips at a concentration of 2,000 cells/cm2, and cultured for 24 hours prior to 
inhibitor exposure, followed by a further 48 hour period of exposure. Inhibitor 
concentrations were decided based on the results obtained during the viability experiment 
(n=2). The same DMSO- and DMSO+ controls were included. The chosen concentrations 
are presented in Table 15. The samples were imaged with a brightfield microscope, before 





Table 15. Inhibitor concentrations used in 2D morphology estimation. 
Inhibitor Concentrations (µM) 
FAK 2, 5, 7, 10 
MEK 10, 30, 60 
ROCK 10, 40, 90, 200 
Blebbistatin 10, 30, 60 
 
 Experiments in 3D 
6.5.1 Preparing the cell-collagen solution 
The collagen I solution was prepared as instructed by the manufacturer [92]. In relation 
to the volume of collagen, 0.025 % of sterile 1 N sodium hydroxide (NaOH) was 
suspended with 10 % D-PBS (10X) (Gibco, Thermo Fisher Scientific) on ice. Rat tail 
collagen I (Gibco, Thermo Fisher Scientific) was then added slowly as a thin ribbon and 
suspended well for three minutes on ice, in order to adjust the pH of the solution. Next, 
the suspension was applied to a cell pellet at a concentration of 1,000,000 cells/mL. The 
solution was kept on ice for the encapsulation. 
6.5.2 Viability and proliferation – 3D 
For the viability assay 50 µL samples from the cell- collagen solution were pipetted into 
a 96 well plate (n=3). The gelation occurred as the gel warmed both at room temperature 
and at 37 °C upon transfer to the incubator. The warming of the solution was aided by 
applying pre-warmed BM on to the gel in droplets. The cells were encapsulated for 24 
hours prior to inhibitor exposure, followed by a 48 h period of exposure. Upon 
experimentation, the inhibitor-containing medium was removed and cultures were treated 
with CCK-8 diluted 1:10 in D-PBS and incubated for 3 h at 37 °C. After incubation, 
absorbance at 450 nm was measured using a plate reader. Every experiment was run in 
parallel with five fresh standards prepared in two-fold dilutions of cell concentration 
(n=3), which were used to form a standard curve in order to extrapolate the viable cell 





Table 16. Inhibitor concentrations used in 3D viability assays. 
Inhibitor Concentrations (µM) 
FAK 2, 5, 7, 10 
MEK 10, 30, 50, 70, 100, 200 
ROCK 25, 50, 100, 200 
Blebbistatin 10, 20, 40, 80 
 
6.5.3 Cell morphology 
The 50 µL 3D cell morphology assay samples from the cell-collagen solution were 
pipetted on pre-warmed sterile glass coverslips as droplets (n=2). The gelation occurred 
upon warming, as previously described. The cells were encapsulated for 24 hours, prior 
to inhibitor exposure, followed by a 48 hour period of exposure. The inhibitor 
concentrations used are listed in Table 17. The samples were fixed and immunostained 
as previously described. 
 
Table 17. Inhibitor concentrations used in 3D morphology assessment. 
Inhibitor Concentrations (µM) 
FAK 10 
MEK 100, 200 










 Experimental flow-chart 
In Figure 3, the experimental workflow is illustrated. 
 
 
Figure 3. Illustration of the work-flow, providing information on the seeding 
material and executed experiments. 
Detachment of P4 
cells


























 MEK inhibitor results were inconclusive 
Several experiments were performed with MEK inhibitor in the viability assay to 
optimize the culture density, time-point and number of dosages. All of the trialed 
combinations, but not all results, are presented in Figure 4. The results of the 2D assay 
are presented as mean values (n=5) with standard deviations, whereas the results of the 
3D assay are presented with individual data points for each replicate, due to their wide 
standard deviation. All results were normalized relative to the DMSO+ control (100 %). 
In addition, the DMSO- control is provided as a reference. The 24 hour time-point was 
rejected with the 48 hour time-point of two doses. Instead a half-way was chosen; 48 
hours with one dose was considered to provide the maximum effect with minimum 
disruption of the culture. This set-up was used for all inhibitors both in the viability assay 
and for the morphological assessments. In the MEK inhibitor 2D assay, no correlation 
between the different results could be seen. In addition, the 48 hour assay with only one 
dose was considered unsuccessful, as no twofold dilutions could be made. 
 
Figure 4.  MEK inhibitor viability results. CCK-8 assay results presented as percent 
viability vs. inhibitor concentration. Given results vary in time-point and number 
of medium changes. The DMSO+ control is taken as a comparison (100 %) and 
DMSO- is presented as a mean value, a color coordinated square. Values are 
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Considerably higher concentrations of inhibitors were used in the 3D assay, in order to 
achieve maximum effect. The results from 3D viability assay are presented in Figure 5. 
The results are provided as stand-alone and compared to the DMSO+ control mean value 
(100 %). The DMSO- control replicates are provided as a reference. There was high 
standard deviation between the replicates and therefore no differences in viability could 
be seen between the concentrations. 
 
Figure 5.  MEK inhibitor viability results from the 3D model. CCK-8 assay results 
presented as percent viability vs. inhibitor concentration, after 48 h of exposure 
with one inhibitor dose. The DMSO+ control mean value is taken as a comparison 
(100 %) and DMSO- is presented as a square. Each data point represents a single 
replicate, due to the high standard deviation, and a trend line is shown. 
When comparing the chosen set-up from the 2D viability assay with the 3D results, no 
correlation can be seen (Figure 6). However, if the 2D assay for the 48 hour exposure 
with one dose is considered as unsuccessful and 3D assay as successful experiment, the 
results show that the inhibitor does not affect the viability of the cells, even with higher 
concentrations. 
Representative bright field images were taken from both TCP and glass coverslips in 2D. 
The results are presented in Figure 7 and Figure 8. No major differences were observed 
between different concentrations. However, a difference can be seen between the culture 
surfaces. The MEK inhibitor formed aggregates or crystals when added to the cell culture. 
These crystals are visible in Figure 5 at 90 µM, shaped like twigs. In order to rule out the 
possibility that the HS had induced formation of the aggregates, a simple test comparing 
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conditions (data not shown), and warming the solutions did not help to dissolve the 
crystals, so the aggregates could not be avoided, and were visible at high concentrations. 
 
 
Figure 6. Comparison of the effect of MEK inhibitor on viability between 2D and 3D 
models. CCK-8 assay results are presented as percent viability vs. inhibitor 
concentration. Given results vary in culture models. Both assays were run after 
48 h of inhibitor exposure after one dose. The DMSO+ control is taken as a 
comparison (100 %). Values are presented as mean values, 2D) n=5 and 3D) 


























Figure 7.  Brightfield images after 48 h of MEK inhibitor exposure at (A) 90, (B) 70, 
(C) 50 and (D) 30 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO, 
cultured in a 96 well plate, scale bar 100 µm. 
 
Fluorescence micrographs of cells exposed to MEK inhibitor are presented in Figure 9. 
DMSO- controls were imaged for comparison. Some change in morphology and actin 
intensity can be observed after 30 µM. Moreover, cells treated with 60 µM of the inhibitor 
seemed to be ruffled from the edges, with a higher intensity of vinculin. In addition, some 





Figure 8. Brightfield images after 48 h of MEK inhibitor exposure at (A) 60, (B) 30, 
(C) 30 and (D) 10 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO, 





Figure 9. Fluorescent images of the MEK inhibitor 2D morphology samples. Cells 
were exposed to MEK inhibitor for 48 h at (A) 10, (B) 30, (C) 60 and (D,E,F) 0 
µM without DMSO. F-actin (red), vinculin (green), nucleus (blue), scale bar 50 
µm. 
 
In Figure 10, the 3D control samples from immunostaining and confocal imaging are 
presented. The images are formed from z-plane images as sums in a z-stack. There is little 
difference to be detected between the DMSO+ and DMSO- samples. Cells are elongated 
and reaching through the Col-I matrix in all directions. In the second DMSO- image 
(Figure 10, C) a z-stack from the bottom of the culture is presented. Here the cells appear 
to have migrated to the bottom of the samples, to the glass. This apparent durotaxis was 
observed in all samples.  
The MEK inhibitor-treated samples did not change morphology as a response to the 
exposure. Both high concentration samples, 100 and 200 µM, were imaged (Figure 11). 






Figure 10.  Fluorescent images of 3D sample controls. Images were formed 
from confocal microscope z-stacks: (A) DMSO+, 11 z-planes (B) DMSO-, 32 z-
planes and (C) DMSO-, 11 z-planes, shift between planes 0.82 µm. The z-stack is 
a sum of all z-planes. Cells were exposed to the ROCK inhibitor for 48 h. F-actin 






Figure 11.  Fluorescent images of a MEK inhibitor exposed 3D samples. Images 
were formed from confocal microscope z-stacks: (A) 100 µM, 15 z-planes, (B) 200 
µM, 42 z-planes, (C) DMSO-, 32 z-planes, shift between planes 0.82µm. The z-
stack is a sum of all z-planes. Cells were exposed to the MEK inhibitor for 48h. 
F-actin (red), vinculin (green), nucleus (blue), scale bar 50 µm 
 
The inhibitor crystal aggregates caused significant background staining with the DAPI 
dye, even though they were on top of the gel and far from the cells being imaged. These 
aggregates of butterfly-shape are presented in Figure 12. In this z-stack, no nuclei were 
distinguishable from the intense staining of the aggregates. This could not be corrected 





Figure 12. Fluorescent image of a MEK inhibitor-exposed 3D sample, 
presenting inhibitor aggregates. Images were formed from confocal microscope 
z-stacks: nine z-planes, shift between planes 0.82 µm. The z-stack is a sum of all 
z-planes. Cells were exposed to 200 µM of MEK inhibitor for 48 h. F-actin (red), 
vinculin (green), aggregates (blue), scale bar 100 µm. 
 
 ROCK inhibitor induced significant changes in morphology 
For ROCK inhibitor the viability assay was performed with two set-ups: after 24 and 48 
hour exposure. In addition, the 48 hour exposure was executed with two different inhibitor 
ranges, first with two-fold dilutions and then with a range with 10 µM intervals. The 
viability results are presented in Figure 13. Although no visible changes in the viability 
were detected, a correlation between exposure time and cell viability was visible. 
Although the second 48 hour range appears to indicate cell proliferation, this is more 
likely to be due to inaccurate preparation of different concentration solutions, caused by 
not using the twofold dilution method. 
For the 3D viability assay, higher concentrations were chosen to achieve maximum effect. 
The results with ROCK inhibitor are presented in Figure 14. As with the MEK inhibitor, 
the 3D results are presented with one data point per replicate. All samples in 2D and 3D 
were normalized relative to the DMSO+ control mean value (100 %). The DMSO- 
47 
 
controls are provided as a reference. There was some variation between the replicates, but 
a descending trend can be detected. However, this decrease in viability only reaches about 
80 % compared to the control, even though the concentration of the inhibitor is extremely 
high. 
 
Figure 13. ROCK inhibitor viability results from 2D model. CCK-8 assay 
results presented as percent viability vs. inhibitor concentration. Given results 
vary in time-points. DMSO+ control is taken as a comparison (100 %) and 
DMSO- is presented as a mean value, a color coordinated square.  Values are 
presented as mean values (n=5) with standard deviation. 
 
For the comparison between the two models, the successful twofold dilution range (1st 48 
hour range) assay was chosen to present the 2D model. As can be seen from Figure 15, 
there are no similarities between the two models. The 2D model inhibitor treatment seems 
to cause a decrease in viability, whereas the 3D model shows no clear trend.    
The representative brightfield images of both TCP and glass cultures are presented in 
Figure 16 and Figure 17. In addition to morphological changes corresponding to surface 
type and possibly stiffness, the cells seemed to be leaving or forming protrusions in all 
directions in a dose-dependent manner. The morphological changes were detectable at ≥8 


























Figure 14.  ROCK inhibitor viability assay results from 3D model. CCK-8 assay 
results presented as percent viability vs. inhibitor concentration, after 48 h of 
exposure with one inhibitor dose. The DMSO+ control mean value is taken as a 
comparison (100 %) and DMSO- is presented as a square. Values are presented 
as individual data point for each replicate, with a trend line. 
 
Figure 15. ROCK inhibitor viability assay result comparison between 2D and 
3D models. CCK-8 assay results are presented as viability-% vs. inhibitor 
concentration. Both assays were run after 48 h of inhibitor exposure. Given 
results vary in culture models. The DMSO+ control is taken as a comparison (100 












































Figure 16.  Brightfield images after 48 h of ROCK inhibitor exposure at (A) 90, 
(B) 64, (C) 8 and (D) 4 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO, 
cultured in a 96 well plate, scale bar 100 µm. 
 
The protrusion formation can be seen clearly from the fluorescent images taken from 
immuno-stained samples. These images are presented in Figure 18. The 10 µM exposure 
still maintains a morphology close to the control, but the actin bundles seem to have 
decreased. In 40 µM exposure the protrusions are very visible and polarization is lost in 
the cells. The size of cells varied greatly at ≥90 µM exposure. It should also be noted that 
in the 90 µM culture, multi-nucleated cells were present. At the very high concentration 
of 200 µM, the cells were rounded and no cytoskeletal organization could be recognized. 
Vinculin is very much centered according to the nucleus. In addition, the protrusions seem 
to be more like tails and could possibly be the result of the cell retracting, rather than 





Figure 17. Brightfield images after 48 h of ROCK inhibitor exposure at (A) 200, 
(B) 90, (C) 40 and (D) 10 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO,  






Figure 18. Fluorescent images of the ROCK inhibitor 2D morphology assay. 
Cells were exposed to ROCK inhibitor for 48 h at (A) 10, (B) 40, (C) 90, (D) 90 
and (E) 200 µM, (F) 0 µM without DMSO. F-actin (red), vinculin (green), nucleus 




Similar morphological changes were also visible in 3D. In Figure 19, a fluorescent image 
of confocal z-stacks are presented. Long protrusions reach inside the gel, but very little 
F-actin is visible, whereas vinculin was stained very strongly. 
 
Figure 19. Fluorescent images of a ROCK inhibitor exposed 3D sample. Images 
were formed from confocal microscope z-stacks: (A) 100 µM, seven z-planes, (B) 
200 µM, eight z-planes and (C) DMSO-, 32 z-planes, shift between planes 0.82µm. 
The z-stack is a sum of all z-planes. Cells were exposed to the ROCK inhibitor for 




 Blebbistatin affected both viability and morphology 
The 2D viability results with Blebbistatin are presented in Figure 20. Blebbistatin was 
experimented at 24 hours and twice at 48 hours. The results were in alignment between 
the 24 hour and the first 48 hour experiment, but was less successful in the second range 
as the dilutions were not executed in twofold dilutions. With Blebbistatin there is a clear 
change in viability, determining a critical threshold affecting viability between 16 and 32 
µM. 
 
Figure 20. Blebbistatin treatment viability assay results from 2D model. CCK-
8 assay results presented as percent viability vs. inhibitor concentration. Given 
results vary in time-points. The DMSO+ control is taken as a comparison (100 
%) and DMSO- is presented as a mean value, a color coordinated square. Values 
are presented as mean values (n=5) with standard deviation. 
In 3D the change in viability after Blebbistatin treatment was not as marked as in 2D. The 
results are illustrated in Figure 21. The used concentrations were quite close to the 
concentrations used in the 2D model. The replicates had little variation, excluding the 10 
µM samples and therefore it appears that there was a decreasing trend in a dose-dependent 
manner. 
The first range of 48 hour exposure with twofold dilutions was chosen to be the most 
insightful assay. The results were compared with the 3D viability assay results (Figure 
22). Both models show a similar decrease in viability in a dose-dependent manner, when 
excluding the high standard deviation of the 10 µM (3D) and 16 µM (2D) samples. 
However, the decreasing effect is more subtle in 3D and does not reach greater than 50 


























Figure 21. Blebbistatin treatment viability assay results from 3D model. CCK-
8 assay results presented as percent viability vs. inhibitor concentration, after 48 
h of exposure with one inhibitor dose. The DMSO+ control mean value is taken 
as a comparison (100 %) and DMSO- is presented as a square. Each data point 
represents one replicate, with a trend line. 
 
 
Figure 22. Blebbistatin treatment viability assay result comparison 2D vs. 3D. 
CCK-8 assay results are presented as percent viability vs. inhibitor concentration. 
Both assays were run after 48 h of inhibitor exposure. Given results vary in culture 
models. The DMSO+ control is taken as a comparison (100 %). Values are 







































The corresponding images of Blebbistatin-treated cultures on TCP and glass are presented 
in Figure 23 and Figure 24, respectively. Morphological changes were visible on both 
materials. With higher concentrations, the cells seem more round and retracting. This is 
visible at ≥16 µM treatment. Much like with MEK inhibitor, Blebbistatin formed 
aggregates at higher concentrations. These aggregates, shaped as rods, can be seen in 
Figure 24 at 60 µM. 
 
  
Figure 23. Brightfield images after 48 h of Blebbistatin exposure at (A) 60, (B) 
32, (C) 16 and (D) 8 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO, 





Figure 24. Brightfield images after 48h of Blebbistatin exposure at (A) 60, (B) 
30, (C) 30 and (D) 10 µM, (E) 0 µM, with DMSO and (F) 0 µM without DMSO, 
cultured on a glass covers in a 24-well plate, scale bar 100 µm 
 
The samples cultured on glass covers were immunostained and assessed for cytoskeletal 
organization or FA changes. These fluorescent images are presented in Figure 25. When 
compared to the DMSO- control, the cells treated with 10 µM of the inhibitor showed no 
difference in morphology. However, at the two higher concentrations, F-actin bundles 
appeared to be less dense and sparser. Moreover, the cells were larger in size and at 60 





Figure 25. Fluorescent images of the Blebbistatin-treated 2D morphology 
assay. Cells were exposed to Blebbistatin for 48 h at (A) 10, (B) 30 and (C) 60 
µM, (D) 0 µM without DMSO. F-actin (red), vinculin (green), nucleus (blue), 
scale bar 50 µm 
 
When cultured in Col-I, the Blebbistatin-treated cells showed neuronal resemblance. The 
confocal imaging results are presented in Figure 26. The cells showed round somata with 
protrusions in several directions. In addition, the cells had minimal actin organization 




Figure 26. Fluorescent images of Blebbistatin exposed 3D samples after 48 h. 
Images were formed from confocal microscope z-stacks: (A, B) 80 µM, 11 z-
planes, and (C) DMSO-, 32 z-planes, shift between planes 0.82µm. The z-stack is 
a sum of all z-planes. F-actin (red), vinculin (green), nucleus (blue), scale bar 50 
µm. 
 
 A critical point was determined for FAK inhibitor 
The FAK inhibitor was tested with the viability assay only once in 2D. The representative 
viability curve is presented in Figure 27. As was with the other inhibitors, DMSO+ was 
used as the reference value (100 %). The different cultures were exposed to eight 
concentrations of the inhibitor, performed in twofold dilutions, for 48 hours before the 
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assay was executed. The graph has the typical shape expected. The viability decreased by 
almost 40 % at the lowest used concentration (0.1 µM) and reached full apoptosis at a 
concentration of only 6.4 µM. 
In the 3D viability assay, the same concentration range was used as in 2D, but with regular 
intervals between concentrations (Figure 28). Full apoptosis was not achieved at the 
highest concentration (10 µM), but the dose-dependent viability loss is clearly visible. 
The drop in viability after the lowest concentration (2 µM) is not as sharp as in 2D, but 
takes place in all replicates. It should be noted, that between 7 µM and 10 µM there is 
little to no difference in viability change. 
When comparing the two models it is clear that FAK inhibitor indeed affects the cell 
culture viability (Figure 28). However, slightly higher concentrations are needed in 3D to 
achieve the same results as in 2D. Nevertheless, the most drastic drop in viability takes 
place in the range of ~4–8 µM in both models. 
 
Figure 27. FAK inhibitor viability assay results 2D. CCK-8 assay results 
presented as percent viability vs. inhibitor concentration. Exposure time 48 h. The 
DMSO+ control is taken as a comparison (100 %) and DMSO- is presented as a 

























Figure 28. FAK inhibitor treatment viability assay results from 3D model. CCK-
8 assay results presented as percent viability vs. inhibitor concentration, after 48 
h of exposure with one inhibitor dose. The DMSO+ control mean value is taken 
as a comparison (100 %) and DMSO- control is presented as a square for 
comparison. Each data point represents a single replicate, with a trend line. 
 
Figure 29. FAK inhibitor treatment viability assay result comparison 2D vs. 3D. 
CCK-8 assay results are presented as percent viability vs. inhibitor concentration. 
Given results vary in culture models. The DMSO+ control (mean value) is taken 
as a comparison (100 %). Values are presented as mean values, 2D) n=5 and 3D) 








































The 2D model morphology assay brightfield images from TCP are presented in Figure 
30. Here the radical morphological change correlates with the viability tests; there is a 
clear difference between concentrations 3.2 µM and 6.4 µM. At the two highest inhibitor 
concentrations, the cells retracted and adopted a rounded morphology, whereas at the 
lower concentrations, the cells remained in spindle form, as in the controls. 
Cells cultured on glass coverslips and treated with FAK inhibitor did not survive, 
although the DMSO- controls seeded in parallel did survive. Therefore, no 
immunostaining images are provided from the 2D model. It may have been that the 
DMSO reacted with the glass, causing the cells to die. The experiment was not repeated 
due to limited time resources. 
 
Figure 30. Brightfield images after 48 h of FAK inhibitor exposure at (A) 12.8, 
(B) 6.4, (C) 3.2 and (D) 1.6 µM, (E) 0 µM, with DMSO and (F) 0 µM without 




The fluorescent images from the 3D confocal imaging are presented in Figure 31. Only 
the highest 3D model inhibitor concentration was stained for the morphological 
assessment. The results correlate with the 2D brightfield images, as the cells have very 
round somata with retracting tails following them. In addition, some apoptotic debris was 
visible in the samples, showing as vinculin clusters without the nucleus (Fig. 31, 10 µM, 
right). This correlates with the viability assays. 
 
Figure 31. Fluorescent images of FAK inhibitor-exposed 3D samples. Images 
were formed from confocal microscope z-stacks: (A) 10 µM, 10 z-planes, (B) 10 
µM, 9 z-planes, and (C) DMSO-, 32 z-planes, shift between planes 0.82 µm. The 
z-stack is a sum of all z-planes. Cells were exposed to the FAK inhibitor for 48 h. 




 Determining IC50 values 
As a clear decreasing viability was detected in the 2D model of Blebbistatin and both 
models of FAK inhibitor, the IC50 values can be determined. The effect on viability was 
plotted against the logarithmic scale of inhibitor concentrations and the values were 
recorded at 50 % of effect. The plotting is presented in Figure 32 and the calculated values 
are stated in Table 18. 
 
Figure 32. IC50 calculations for Blebbistatin in 2D and FAK inhibitor in both 
models. Results are presented as mean values without standard deviation and 
plotted as loss of viability against logarithmic concentration values (µM). Here 
the results were read at 50 % loss of viability. All results were achieved through 
48 h exposure and one inhibitor dose. 
 
Table 18. Calculated IC50 values for the successful viability assays 
Inhibitor and model Read value at 50 % 
viability loss 
IC50 
Blebbistatin 2D 3.35 ~28.5 µM 
FAK inhibitor 2D 1.25 ~3.5 µM 




























 MEK inhibitor 
The viability assay with MEK inhibitor gave inconclusive results. The first two set-ups 
in 2D – 24 hour exposure and 48 hour exposure with two doses – seemed to have a 
declining trend (Figure 4). However, both barely reached 50 % viability loss and the 
standard deviation is high, especially after 24 hour exposure. The results achieved after 
48 hour exposure with one dose were unsuccessful. It may be considered that some 
secondary signaling pathways were trying to balance and overrule the effect of the 
inhibited MEK, but such an effect might not expected to be as strong and fluctuating 
throughout different concentrations. It is therefore more likely that there was pipetting 
error in the inhibitor dilutions. The volumes used in the dilutions were extremely small 
and therefore the probability of manual error was high. In 3D, there was still no strong 
evidence of the MEK inhibitor affecting cell viability (Figure 5). In addition, the 
variability between replicates was high. Based on these results, it could be suggested that 
the MEK-ERK pathway does not directly regulate the viability of cells. Yet, the pathway 
is a key signaling pathway for several cell functions. Thus, the critical point of the MEK 
inhibitor should be estimated through other means. 
The results are in agreement with the morphological assessment. Small changes were 
detected in the 2D model in a dose-dependent manner as the actin intensity decreased at 
≥30 µM and vinculin build-up was visible at the ruffled edges of the cells at ≥60 µM 
(Figure 9). This was supported by the confocal images, where there are only mild 
differences between the MEK treated cultures and the DMSO- control. The vinculin 
intensity decreased and the cells looked a bit more ruffled from the edges, but the 
elongated network of cells still remained. The results indicate that there are no major 
morphological effects resulting from MEK inhibitor treatment and no clear critical point 
can be determined. 
Previously, MEK inhibitor has mostly studied for its effects on differentiation. The 
connection to osteogenesis has been demonstrated on several occasions (Table 5). Thus, 
as the results of the present study do not provide information on the critical point, the 
effects in differentiation could be measured instead. This is supported by the fact that in 
the present study, only a mild change was detected at concentrations of 30 and 60 µM, 
whereas in the literature, significant changes were detected with 50 µM (Table 5). 
The crystal formation of the inhibitor caused challenges throughout the project. The 
crystals in the 2D assays could not be rinsed from the culture and caused background 
staining in the brightfield imaging. The crystals also attached to the tops of the hydrogels, 
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causing strong background staining and illuminating throughout the gel. This complicated 
the imaging process. It should therefore be considered that the inhibitor may not have 
reached the cells in the 3D culture, due to its aggregation outside the gels. In conclusion, 
due to the contradicting results and problems with the inhibitor aggregates, no conclusion 
concerning the effects of MEK can be made with any confidence. Instead, the crystal 
formation issue should be solved and the assays should be performed again. As the 
medium components and heating were already tested as a solution, the next step should 
be to test a fresh batch of the MEK inhibitor. 
 ROCK inhibitor 
For the ROCK inhibitor, the viability results in 2D showed closer correlation than for the 
MEK inhibitor. Again, there was some decline in cell viability in the 24 hour and the first 
48 hour assay. In contradiction, the second 48 hour showed no decrease in viability. There 
also seemed to be some proliferation at the lower concentrations in comparison to the 
DMSO+ control. The second assay with the 48 hour exposure could be considered to be 
unsuccessful, since twofold dilution was not used to prepare the samples, resulting in 
likely pipetting error. In 3D, an increase in viability was recorded at lower concentrations, 
with a greater decline at higher concentrations. This could indicate that there is, in fact, 
an effect on viability, but that higher concentrations are needed than in 2D. Nevertheless, 
as the highest used concentration was quite high, the effects would most likely be due to 
toxicity, rather than being due to the effect of inhibiting the signaling pathway. Based on 
these results it is suggested that the ROCK inhibitor does not affect the viability of the 
cells. 
By contrasts, the morphological assay showed a change in cell morphology in a dose-
dependent manner, and the critical point, an IC50 of ~6 µM, could be estimated from the 
images. This value was estimated based on the fact that clear morphological changes were 
detected at 8 µM, but not at 4 µM (Figure 16). This IC50 value is rather small when 
compared to the values referred to in the literature, which most commonly ranging from 
10-100 µM. However, downregulation of pFAK and pERK was reported after 5 µM 
inhibitor treatment on hBMSCs [85] and abrogation of osteogenesis at 10 µM in hMSCs 
[18]. In addition, 10 µM inhibitor treatment of mMPC leading to ruffling of the cell edges 
was detected only after 1 hour [81]. Therefore, it could be concluded that the estimated 
IC50 correlates with the literature. Higher concentrations on other studies could be due 
to the difference in cell type.  
The morphological changes were observed in both models, although the concentrations 
affecting morphology were threefold higher in 3D. The expected loss of actin fibers was 
visible throughout the images (Figure 18). In addition, the inhibitor likely caused loss of 
intracellular tension, as multinucleated cells are present (Figure 18, D). FA formation 
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seemed to be presented in bundles and mostly at the edges of the cells. At the highest 
concentration, the cell appeared to be retracting and rounding, and therefore the intensity 
of vinculin was high (Figure 18, 200 µM). The protrusions can be described as resembling 
tails. In agreement, it has been hypothesized in the literature that ROCK inhibition 
induces cell migration [82]. The observable tail has been explained as being an effect of 
inhibited tail detachment and depolymerization of the stress fibers. On the other hand, 
ROCK has been described as being a regulator of imbalance in polarity, controlling the 
fact that there is only one edge leading in the migration, or that cells can have basal and 
apical sides to them. In this sense, these processes could be the result of polarity regulation 
and protrusions are therefore created without control. The results in this study are 
compatible with either theory (Figure 18). 
The ROCK inhibitor has been connected to the differentiation potential of stem cells in 
several studies (Table 9). Typically, differentiation has been linked with osteogenesis, but 
due to the protrusions, there has been some suggestion that there is an association with 
neurogenesis. The neurogenic induction demonstrated by Neuhuber et al. changed the 
morphology of the MSCs, but the effect was reversed after the induction was finished 
[93]. The neurogenic resemblance both in 2D and 3D environment could be tested in 
future. In addition, the reversibility of this morphological change could be studied after 
inhibitor removal. 
 Blebbistatin 
The viability study on Blebbistatin showed the expected trend in 2D and the 3D model 
correlates well. It was possible to calculate a critical point from the 2D assay of the first 
48 hour exposure, with an IC50 of 28.5 µM. This falls within the range of concentrations 
investigated in the literature. For Blebbistatin the most commonly stated concentrations 
have been 50 µM and 5 µM, indicating that perhaps a too high or a too low concentrations 
have been used, respectively.  
There are several reasons why the reliability of the 3D results are questionable, including 
the variability between replicates and the anomaly at 40 µM. Another reason is that the 
viability does not decrease enough to confirm the critical point. Therefore, it is either the 
case that higher concentrations must be investigated in 3D in order for reliable results to 
be achieved, or that cells are less affected in 3D by Blebbistatin than in 2D. 
The morphology of the Blebbistatin-treated cells correlated with the critical point 
calculated from the viability results in 2D. The morphology of the cells was round in the 
brightfield images (Figure 23, A, B, C) and they were larger in size, as indicated by the 
immunostaining (Figure 25, C). The loss of stress fibers indicated changes in other 
pathways such as ROCK and MEK-ERK as explained by [89]. Moreover, intracellular 
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contractility and tension was lost in the higher concentrations as multinucleated cells were 
present and, hence, cytokinesis was likely disabled (Figure 25, C). In 3D, the morphology 
of the cells was quite different. The somata of the cells were rounding as in 2D, but the 
cells seemed to aggregate and create networks of processes. As was stated with the ROCK 
inhibitor, these processes could be intentional protrusions or the result of inhibited tail 
retraction. Nevertheless, the resemblance to neuronal morphology cannot be discarded 
and adipogenic and chondrogenic differentiation has been previously observed, so 
differentiation down various lineages should therefore be tested in future. 
 FAK inhibitor 
The FAK inhibitor provided the most insightful and conclusive results in the present 
study. Based on the viability results, a critical point was determined for both models, with 
IC50 values of ~3.5 µM and ~5.2 µM in 2D and 3D, respectively. In addition, as expected 
from the hypothesis, there was a difference between the two models, with a higher IC50 
in 3D. Few in vitro experiments have previously been conducted, but the concentrations 
that were found in the literature were quite high (10 µM). It should, however, be noted 
that the treated cells were of cancer lineage. Interestingly, Roberts et al. demonstrated cell 
cycle inhibition at 3.3 µM, which is extremely close to the IC50 value obtained in the 
present research. [64] 
The morphology changes of the FAK treated cells were in agreement with the viability 
result, supporting the stated IC50 values. The rounding of the cells indeed correlates with 
the loss of FAs, which is demonstrated in the literature [62]. Moreover, the loss of FAs 
likely led to the detachment of the cells and subsequent anoikis, as detected by the 
viability assay. Unfortunately, the 2D immunostaining was unsuccessful and, thus, the 
loss of FAs cannot be confirmed without further investigation. In the 3D model it is 
thought that too high a concentration was used to demonstrate the morphological changes, 
as the viability was quite low at 10 µM. The cells seemed apoptotic and a lot of cell debris 
was visible around the stained cells. A lower concentration of 7 µM could have 
demonstrated the morphological changes more efficiently. 
There were no signs from the morphological changes that indicated possible stem cell 
fate commitment. However, as FAK is upstream in the mechanotransductive signaling in 
the present study, and a key effector in mechanotransductive response, it is likely that 
when inhibited, the effects diminish ECM-induced differentiation. Hence, differentiation 
should in future be studied in matrices of various stiffnesses at the calculated IC50. 
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 Material speculation 
Several improvements could be made to the culturing conditions. For example the 
hydrogel material could have been replaced with a non-expired hydrogel. On the other 
hand, the controls were performed with the same material and used as a baseline in the 
expired material. Another addition to the material studies could have been a Col-I coated 
2D experiment. However, the 3D material was chosen after the 2D studies were finished 
and due to limited time resources the experiment was not executed.  
To improve the experiments with the hydrogel, the samples could have been taller. As the 
samples were quite low, the cells may have been able to sense the stiff glass cover at the 
bottom of the hydrogel and migrate via durotaxis. This sensing through a thin ECM was 
stated by Tusan et al. demonstrating that cells sense the stiffness of the underlying 
material ≤15 µm [94]. As was estimated with the confocal microscope, the height of the 
used hydrogels were at maximum 30 µm. Therefore, the sensing and possible durotaxis 
might have been avoided with a different mold and increase in height. 
The last material related speculation should be directed to the permeability of the 
hydrogel. No tests were executed to ensure that the inhibitors reached the cells inside the 
gels. Yet, changes were detected in all inhibitors except MEK inhibitor. Suspending 
might have helped. For example, to retrieve the viability assay’s yellow hue entrapped in 
the gels, the solution was pipetted up and down. A similar process could be applied to the 
inhibitors. In addition, the permeability of the material could be tested through a separate 
assay. However, the issue of permeability is inherent when working with 3D matrices. 
 Assessment of the study 
The results of the study may not be accurate due to the limited number to experimental 
repeats and high variability between the groups. This is especially the case with the 3D 
experiments which were not tested with several experiment set-ups and different exposure 
times. Moreover, there were only three replicates. 
The results on morphology can be taken as indicators of the possible effects. The 
morphological changes depend much on the provided ECM as was already demonstrated 
between the TCP and glass covers and, hence, the differences are expected in 3D, as well. 
The material properties can vary greatly in stiffness, degradation and ligand presentation, 
as stated in chapter 3.4. The morphological changes demonstrated here apply only at these 
concentrations in this material, until proven otherwise. 
The first hypothesis of the study was partially proved, as the critical point could be 
calculated for two inhibitors, FAK inhibitor and Blebbistatin. It was concluded that the 
ROCK and MEK inhibitors are not directly implicated in affecting cell viability, based 
69 
 
on the achieved results. The second hypothesis was proven via the morphological analysis 
and the correlation between cell shape and the critical inhibitor concentrations. In 
addition, with ROCK inhibitor, morphological changes brought additional information, a 
possible critical point, where the viability assay did not. The third hypothesis of this study 
predicted a difference between the two models. This was confirmed to be true in the case 
of all the inhibitors tested, indicating that a higher concentration is required for a similar 
effect in 3D compared to 2D. Moreover, new information or at least indications of all 
inhibitors were created throughout this project and study. 
 Conclusions 
The calculated and estimated IC50 values demonstrate the signaling pathway hierarchy 
in mechanotransduction. FAK being the upstream signaling protein, regulator of FAs and 
an activator of the downstream signaling proteins needs only a small concentration (3.5 
µM) of inhibitor to cause significant changes in the mechanotransductive pathway in 2D. 
The disturbance in the pathway caused changes both in viability and morphology. ROCK 
has a key role in the actin stress fiber regulation and is downstream of FAK. In correlation, 
an inhibitor concentration of 6 µM was estimated based on the morphological changes. 
NMMII, being at the very end of mechanotransductive signaling pathways, required the 
highest concentration. The IC50 of 28.5 µM was enough to affect viability and 
morphology of hBMSCs in 2D. The effects of disrupting MEK on mechanotransduction 
were inconclusive and require further investigation.  
 Future outlook 
To conclude on the weak links of the project, in the future, the study could be improved 
by four aspects: dilution, repetition, material and assays. As the great variation between 
the replicates and the unexpected fluctuation in the viability response was most likely due 
to pipetting error, the dilutions could be performed in stages, in order to pipet larger 
volumes. The dilutions should also be performed in two-fold dilutions as this was 
demonstrated to be most reliable. Furthermore, automated pipetting technology could be 
used to prepare the inhibitor solutions from the stock solutions, almost entirely removing 
human error. Repetitions should be performed on all inhibitors to confirm the results, but 
the emphasis should be on the 3D material, which was only tested once. To define the 
critical point more accurately, various twofold dilutions providing different 
concentrations could be used. 
Another aspect to be added, is to follow the changes in the material during the study. The 
collagen fibers could be stained and imaged before and after the inhibitor exposure. Here, 
not only the morphological changes in the cells could be followed stage by stage, but also 
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the changes in cells ability to reform their surrounding could be assessed, as both are 
stated as effects of mechanotransduction. 
As mechanotransduction and the used inhibitors are connected to differentiation of stem 
cells, the differentiational assays should be added to the study. These studies could be 
performed through mineralization or lipid staining to detect osteogenic or adipogenic 
indication, respectively. The studies could also be taken further by measure the mRNA 
expression of known proteins as stated in chapter 2. For example, Runx2, PPARγ and 
Sox9 expression could be tested for osteogenesis, adipogenesis and chondrogenesis, 
respectively. In addition, the expression of nestin could be tested for neurogenic 
commitment. 
The most important improvement to the present study is to follow the decrease in the 
active forms of the targeted signaling proteins. Through Western blot the decrease in the 
activated forms could be detected and, therefore, the functionality of the inhibitors 
confirmed, both in 2D and 3D. It would also be highly interesting to measure the indirect 
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